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1 INTRODUCTION 
1.1 Drug metabolism 
 
The majority of drugs undergo a variety of chemical reactions in the liver and, to a much 
lesser extent, in other organs (e.g., intestinal wall, kidney, lungs). Such reactions include 
oxidation, reduction, hydrolysis, and conjugation (with glucuronic acid, amino acids, acetate, 
sulphate, and methyl groups) and are directed towards the production of metabolites that are 
more ionized, more water-soluble, and less capable of penetrating cell membranes and being 
sequestrated in tissues. The more polar or water-soluble a compound becomes, the more 
readily it is excreted through the kidney and hepato-biliary system. This biotransformation is 
extremely important because most drugs are lipid-soluble weak electrolytes so that they 
would be readily reabsorbed through the renal tubule or intestine and remain in the body. The 
rate of metabolism may be influenced by many factors among which the genetic make-up of 
the individual and drug interactions are the most important. Metabolism of some drugs, the 
acetylation of isoniazid being the best example, can proceed at a rapid rate in one subgroup of 
the population and at a slow rate in another genetically defined subgroup of the population. A 
slow rate may be due to the deficiency of a specific enzyme because of some genetic defect 
and results in an increased sensitivity to drugs. For example, in subjects with acetyltransferase 
deficiency, the speed of acetylation and inactivation of isoniazid is decreased and 
consequently the usual doses of the drug will produce toxic effects. 
1.1.1 Specific reactions in drugs metabolism 
 
The specific reactions in drugs metabolism are often divided into Phase-I and Phase-II. Phase-
I DMEs, many of which are cytochromes P450, sometimes participate in detoxification of 
reactive substrates. But they are more often involved in the activation of inert protoxicants, 
promutagens and procarcinogens to electrophilic intermediates that can bind as adducts to 
proteins or DNA and/or cause oxidative stress (Dalton et al., 1999; Kidd et al., 1999; Nebert, 
2000). Phase-II DMEs (e.g. methyltransferases, UDP glucuronosy-ltransferases, glutathione 
transferases, sulfo-transferases) are sometimes involved in metabolic activation (Nebert et al., 
1996), but they usually conjugate various Phase-I products and other reactive intermediates to 
form water-soluble derivatives, completing the detoxification cycle.  
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Therefore, it seems likely, that genetic differences affecting the expression of Phase-I and 
Phase-II DME might be crucial factors in defining susceptibility to toxicity or cancer caused 
by drugs and other environmental pollutants. Hundreds of genes coding for drug metabolizing 
enzymes exist in the human genome. Polymorphism in several such genes causing high levels 
of one enzyme and low levels of another enzyme in a specific pathway involved in the  
metabolism of a particular environmental pollutant could lead to 30- or more than 40-fold 
differences between two individuals in response to that foreign chemical (Nebert, 2000). 
 
 
Table 1. Phase-I and phase-II DMEs 
 
It is now well recognized that adverse drug reactions may be caused by specific drug-
metabolizer phenotypes. This is illustrated by the severe and potentially fatal hematopoietic 
Enzyme 
class  
Reaction type  Enzymes  
Phase I DMEs 
Hydroxylation, N- and O- dealkylation, 
desamination, oxidative dehalogenation  
Cytochrome P450 monooxygenases  
N- and S-Oxidation  Cytochrome P450 monooxigenases,  
flavin monooxigenases  
Dehydration  Alcohol dehydrogenases  
Oxidation  
 
Dehydration of amines  Monoamin oxidases  
Reduction  
 
Carbonyl reduction  Carbonyl reductases  
Hydrolysis of epoxides  Epoxide hydrolases  
Hydrolysis of esters  Carboxylesterases  
Hydrolysis  
Hydrolysis of peptides  Peptidases  
Oxidation of superoxide anions  Superoxide dismutases  Others  
 
Peroxidation  Glutathione peroxidases  
Phase- II DMEs 
Conjugation  Glucuronosylation  UDP-glucuronosyltransferases  
 Sulfation  Sulfotransferases  
 Acetylation  O- and N-acetyltransferases  
 Methylation  O-, N- and S-methyltransferases  
 Glutathione S-conjugation  Glutathione S-transferases  
 
*Adapted from Elke Störmer, Dissertation, Berlin, 2001. 
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toxicity that occurs when thiopurine methyltransferase-deficient patients are treated with a 
standard dose of azathioprine or mercaptopurine (Krynetski and Evans, 1998).  
Another example is the slow acetylator phenotype that has been associated with hydralazine-
induced lupus erythematosus isoniazid-induced neuropathies, dye-associated bladder cancer, 
and sulfonamide induced hypersensitivity reactions. In all cases, acetylation of a parent drug 
or an active metabolite is an inactivating pathway. N-Acetyltransferase is an enzyme that 
conjugates substrates with a more water- soluble small molecular moiety. Such conjugation 
reactions are frequently, but not always, detoxifying, in that they often "mask" a more reactive 
functional group and usually enhance urinary or biliary excretion of substrates. There are 
many examples in which the combination of a genetic defect in a conjugation  pathway ( Fig. 
1, right) coupled with a wild-type phenotype for  an oxidation pathway (Fig.1, left), or other 
chemical modifications, results in a phenotype particularly pre-disposed to adverse effects 
from a medication or environmental substance. 
 
 
 
Fig. 1. Participation of specific human liver cytochrome P450 enzymes (left side) and phase-II-enzymes 
(right side) in drug metabolism. The sizes of the segments refer to the relative number of drugs 
metabolized by the respective enzyme, e.g. about 40% of all currently used drugs are metabolized by 
cytochrome P450 3A enzymes (bright blue segment). Figures taken from (Evans and Relling, 1999). 
 
 
As one example, increased CYP1A activity (an enzyme catalyzing a phase-I oxidation 
reaction), coupled with slow acetylation (a phase- II conjugation reaction), resulted in less 
myelosuppression from the active metabolites of the anticancer agent amonafide (Ratain et al., 
1996, Evans and Relling, 1999).  
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Because every individual has a combination of drug- metabolizer phenotypes, given the large 
number of enzymes involved in drug metabolism, it is apparent that some individuals are 
destined to have unusual reactions to drugs or to combinations of drugs due to the coincident 
occurrence of multiple genetic variants in drug- metabolizing enzymes. Such an alignment of 
genotypes, particularly when coupled with polymorphisms in drug receptors, is likely to 
constitute part of the mechanism for so-called idiosyncratic drug reactions. In addition to 
detoxifying and eliminating drugs and metabolites, drug-metabolizing enzymes are often 
required for activation of prodrugs. Many opioid analgesics are activated by CYP2D6 
(Krynetski and Evans, 1998), rendering the 2 to 10 % of the population who are homozygous 
for non-functional CYP2D6 mutant alleles relatively resistant to opioid analgesic effects. It is 
thus not surprising that there is remarkable interindividual variability in the adequacy of pain 
relief when uniform doses of codeine are widely prescribed. For many genetic polymorphisms 
of drug-metabolizing enzymes, there is no evident phenotype in the absence of a drug 
challenge, perhaps because these enzymes are not critical for metabolism of endogenous 
compounds in physiologically essential pathways. However, some drug- metabolism 
genotypes may result in a phenotype in the absence of drug; for example, it has been 
postulated that CYP2D6  poor metabolizers are less pain tolerant than extensive metabolizers 
because of a defect in synthesizing morphine from codeine (Sindrup et al., 1993b), and that 
certain forms of dihydropyrimidine dehydrogenase deficiency are associated with mental 
retardation (Diasio, 1998). Moreover, the risk of some cancers has been linked to 
polymorphisms in drug-metabolizing enzymes, which may be due to an impaired ability to 
inactivate exogenous or endogenous mutagenic molecules. As depicted in Fig.1 CYP3A4 is 
the human enzyme known to be involved in the metabolism of the largest number of 
medications. Thus far, no completely inactivating mutations have been discovered in the 
human CYP3A4 gene, although a common polymorphism in the CYP3A4 promoter has been 
recently described (Rebbeck et al., 1998). For enzymes that apparently do not have critical 
endogenous substrates (for example, CYP2C19, CYP2D6, and TPMT), the molecular 
mechanisms of inactivation include splice site mutations resulting in exon skipping (for 
example, CYP2C19), gene duplication (for example, CYP2D6), point mutations resulting in 
early stop codons (for example, CYP2D6), amino acid substitutions that alter protein stability 
or catalytic activity (for example, TPMT, NAT2, CYP2D6, CYP2C19, and CYP2C9), or 
complete gene deletions (for example, GSTM1 and CYP2D6). It is remarkable that even for 
rare phenotypes such as thiopurine methyltransferase deficiency (which occurs in only 1 in 
300 individuals), a small number of recurring mutations have been shown to account for most 
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of the mutant alleles in humans (Krynetski and Evans, 1998). For this and other drug-
metabolizing genes, the frequency of SNPs and other genetic defects appears to be more 
common than the frequency of "1 per 1000 base pairs" that is cited for the human genome. 
Perhaps it is because some "drug"-metabolizing enzymes are dispensable or redundant with 
other enzymes (such as CYP2D6 and CYP) that genetic polymorphisms of drug-metabolizing 
enzymes are so common. 
 
1.2 Cytochrome P450 Enzymes 
1.2.1  Discovery and Background 
 
The cytochromes P450 are a superfamily of enzymes which are found in all forms of living 
organisms. They are responsible for the metabolism of many endogenous compounds, 
participate in the activation/deactivation of many carcinogens and detoxify many xenobiotics. 
In particular, in humans they metabolise many drugs and hence are of great interest to 
pharmacologists and toxicologists. Its is readily identified by a pronounced absorbance band 
at 450 nm in the soret region of the visible spectrum when the carbon monoxide adduct of the 
reduced hem protein is formed (Pohl et al., 1984) hence the name P450. Human cytochrome 
P450 (P450) enzymes catalyze the metabolism of a wide variety of clinically, physiologically, 
and toxicologically important compounds. The concept of a familial inherited component 
modulating drug response was described in the 1950s, often in connection with case- reports 
of unexpected drug response (Hughes et al., 1954; Kalow et al., 1956; Evans et al., 1960). The 
variation in drug metabolism  was ascribed to different metabolic rates in the enzymes either 
activating or inactivating the drug. The term pharmacogenetics (the study of heritability of 
drug response) was coined prior to the current knowledge in molecular biology The current 
explosion of interest for this field stems from technological advance, such as the mapping of 
the human genome and SNP (single nucleotide polymorphism) maps constituting the basis for 
our understanding of individual genetic diversity, and the fact that the results of these efforts 
are publicly accessible. Pharmacogenetics has traditionally focused on polymorphic drug 
metabolism, even though hereditary differences in drug receptors and drug transportation 
systems are included in the concept. 
The newer term pharmacogenomics comprises all genetic information concerning drug. 
response, including the large scale systematic search for drug response markers (Bailey et al., 
1998).  
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Genetic polymorphisms in drug- metabolizing enzymes, transporters, receptors, and other 
drug targets have been linked to inter individual differences in the efficacy and toxicity of 
many medications. Pharmacogenomic studies are aiming at elucidating the inherited nature of 
these differences in drug disposition and effects, thereby enhancing drug discovery and 
providing a stronger scientific basis for optimizing drug therapy on the basis of each patient’s 
constitution. Pharmacogenetics can be separated into two basic components, pharmaco-
kinetics (drug metabolism) and pha rmacodynamics (how a drug acts). The cytochrome P450 
isoenzymes are a group of heme- containing enzymes found in the liver embedded primarily 
in the lipid bilayer of the endoplasmic reticulum of hepatocytes, but a remarkable amount is 
also found in the small intestine. CYP takes part in the metabolism of many drugs, steroids 
and carcinogens (Guengerich, 1992). And the recognition of the existence of cytochrome 
P450 hem proteins dates back to the late 1950s, when a carbon-monoxide-binding protein 
pigment was reported to be present in the endoplasmic reticulum of the liver (Klingenberg, 
1958), and to the later identification of the pigment as type cytochrome (Omura and Sato, 
1962; Omura and Sato, 1964a; Omura and Sato, 1964b). Shortly thereafter, the ability to serve 
as terminal oxidase in the metabolism of steroid hormones (Estabrook et al., 1963) and 
xenobiotics (Cooper et al., 1965) was demonstrated. These observations were quickly 
followed by recognition that multiple forms of cytochrome P450 exit in the fragments of 
endoplasmic reticulum, the microsomes (Lu et al., 1971; Guengerich et al., 1982a; 
Guengerich et al., 1982b).  
1.2.2 Function 
 
Cytochromes P450 (P450s) are enzymes involved in the oxidative metabolism of a wide array 
of endogenous and exogenous molecules including steroids, plant metabolites, prostaglandins, 
biogenic amines, drugs, and chemical carcinogens. This broad spectrum of reactions is due to 
multiple P450 isozymes with differing but overlapping substrate specificities. Cytochrome 
P450 proteins in humans are drug meta-bolizing enzymes and enzymes that are used to 
synthesize cholesterol, steroids and other important lipids such as prostacyclins and 
thromboxane A2. These last two are metabolites of arachidonic acid. Mutations in cyto-
chrome P450 genes or deficiencies of the enzymes are responsible for several human diseases. 
Induction of some CYP enzymes is a risk factor for some types of cancers since these 
enzymes can convert procarcinogens to carcinogens. 
 P450 enzymes play a major role in drug interactions. Cytochrome P450 enzymes are heme-
containing proteins. The heme iron in cyto-chrome P450 is usually in the ferric (Fe3+) state. 
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When reduced to the ferrous (Fe2+) state, cytochrome P450 can bind ligands such as O2 and 
carbon monoxide (CO). The basic reaction catalyzed by cytochrome P450 is monoxygenation 
in which one atom of oxygen is incorporated into a substrate (RH); the other one is reduced to 
water with reducing equivalents derived from NADPH. The typical cytochrome P450 
catalysed reaction is: 
 
NADPH  +  H+ +  O2  +  RH  →  NADP+  +  H2 O +  R-OH   
 
Fig. 2 Catalytic cycle of cytochrome P 450 enzymes (Guengerich and MacDonald, 1990)  
 
 
The catalytic cycle represented in the above picture may be summarized as follows: (1) The 
binding of a substrate to a P450 causes a lowering of the redox potential (Ruckpaul et al., 
1985), which makes the transfer of an electron favourable from its redox partner, NADH or 
NADPH. This is accompanied by a change in the spin state of the hem iron at the active site.  
(2) The next stage in the cycle is the reduction of the Fe3+ ion by an electron transferred from 
NAD(P)H via an electron transfer chain that depends on a single specific NADPH P450 
reductase that contains both FAD and FMN as cofactors (Coon et al., 1975) FAD can accept 
electrons from NADPH and FMN functions as the single electron carrier. 
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 (3) An O2 molecule binds rapidly to the Fe2+ ion forming Fe2++ O2. There is evidence to 
suggest that this complex then undergoes a slow conversion to a more stable complex Fe3+ - 
O2 (Archakov et al., 1990). (4) A second reduction is required by the stoichiometry of the 
reaction. This has been determined to be the rate limiting step of the reaction (Imai et al., 
1977). A comparison between the bond energies of O2, O2- , and O2 2- suggest that the Fe3+ - 
O2 2- complex is most favourable starting point for the next stage of the reaction to occur. 
Some microsomal P450 systems may receive the second electron from NADPH through 
cytochrome b5; however the mechanism of this interaction still remains speculative 
(Schenkman and Jansson, 2003). (5) The O2 2-  reaction  with two protons from the 
surrounding solvent, breaking the O-O bound, forming water and leaving an (Fe- O) 3+ 
complex. (6) The Fe- ligated oxygen atom (O) is transferred to the substrate forming an 
hydroxylated form of the substrate. (7) The product is released from the active site of the 
enzyme which returns to its initial state. 
 
1.2.3 Evolution 
 
P-450 mixed-function oxidase are enzymes, that catalyze the reduction of oxygen to water. 
Several studies concerning P450 evolution have been  made based on the examination of the 
phylogenetic tree and its correlation with catalytic activities of cytochrome P450s. The 
earliest P450s are those that now metabolize steroids and fatty acids. The fatty acid-
metabolizing P450 IV family and the steroid-inducible P450 III genes diverged more than 1 
billion years ago. The P450 I and P450 II gene families formed about 800 million years ago 
and these genes are now responsible for the metabolism of drugs and carcinogens (Nelson and 
Strobel, 1987). 
1.2.4 Classification  
 
The classification of the various CYP isozymes employs a three tiered classification based on 
the conventions of molecular biology: the family (members of the same family display > 40 
% homology in their amino acid sequences); subfamily (55 % homology) (Tanaka, 1998) The 
highest concentration of P450 enzymes involved in xenobiotic bio-transformation is found in 
the endoplasmatic reticulum (microsomes) of the liver, but P450 enzymes are expressed in 
almost all tissues.  
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The human microsomal P450 enzymes involved in xenobiotic biotransformation belong to 
three main P450 gene families, namely CYP1, CYP2 and CYP3. Liver microsomes also 
contain P450 enzymes encoded by the CYP4 gene family, the substrates of which include 
several fatty acids and eicosanoids but relatively few xenobiotics. A classification of all 
existing 57 human P450s based on substrate class is given in (Table 2).  
Table 2 Classification of human P450s bassed on major substrate class 
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1.3 Clinical relevance of genetic polymorphisms in drug metabolism 
 
The genetic polymorphisms in drug metabolism and disposition were typically discovered on 
the basis of phenotypic differences among individuals in the poplation (Mahgoub et al., 1977), 
but the framework for discovery of pharmacogenetic traits is rapidly changing. Adverse drug 
reactions are common; they are responsible for a number of debilitating side effects and are a 
significant cause of death following drug therapy (Lazarou et al., 1998). It is now clear that a 
significant proportion of these adverse drug reactions, as well as therapeutic failures, are 
caused by genetic polymorphisms, genetically based interindividual differences in drug 
absorption, disposition, metabolism, or excretion. Most of the commercially available drugs 
are metabolized by the phase- I cytochrome P450 superfamily of DMEs. The clinical 
relevance is best characterized for the genetic polymorphisms in CYP2D6, CYP2C19 and 
CYP2C9 (Stormer et al., 2000a). CYP2D6 play important roles in the metabolism of beta-
blockers, tricyclic antidepressants, antiarrythmic agents, antipsychotic agents and opioids. 
CYP2C19 is involved in the metabolism of proton-pump inhibitors whereas CYP2C9 
metabolizes antidiabetics and anticoagulants. In the recent advances in molecular sequencing 
technology, gene polymorphisms [such as single- nucleotide polymorphisms (SNPs), and 
especially SNPs that occur in gene regulatory or coding regions (cSNPs)] may be the 
initiating discoveries, followed by biochemical and, ultimately, clinical studies to assess 
whether these genomic polymorphisms have phenotypic consequences in patients. This latter 
framework may permit the elucidation of polymorphisms in drug metabolizing enzymes that 
have more subtle, yet clinically important consequences for interindividual variability in drug 
response. Such polymorphisms may or may not have clear clinical importance for affected 
medications, depending on the molecular basis of the polymorphism, the expression of other 
drug-metabolizing enzymes in the patient, the presence of concurrent medications or illnesses, 
and other polygenic clinical features that impact upon drug response. Almost every gene 
involved in drug metabolism is subject to common genetic polymorphisms that may 
contribute to interindividual variability in drug response, are given in ( Table 3).  
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Table 3  Examples of clinically relevant genetic polymorphisms influencing drug metabolism and effects 
According to (Evans and Relling, 1999)  
 
                            
Gene Medications Drug effects linked  
to polymorphism 
 
CYP2C9  
(cytochrome P450 2C9) 
Tolbutamide,warfarin, phenytoin, 
nonsteroidal anti-inflammatoric drugs,   
 
 
Hypoglycemic effect of oral 
antidiabetic drugs, anticoagulant effect 
of warfarin, gastric side effects of 
nosteroidal anti-inflammatory drugs 
 
CYP2D6 
(cytochrome P450 
2D6) 
Beta-blockers, antidepressants, 
antipsychotics: codeine,  
debrisoquin, 
dextromethorophan, encainide, 
flecainide, guanoxan, 
methoxyamphetamine, 
N-propylajmaline, perhexiline, 
phenacetin, phenformin, 
propafenone, sparteine 
 
Cardiac side effects of beta-blockers,  
Anticholinergic side effects of tricyclic 
antidepressants, efficacy of 
antidepressive drugs, 
tardive dyskinesia from antipsychotics, 
opioids side effect and efficacy of 
opioids like codeine and tramadol 
which are bioactivated by CYP2D6,  
efficacy and adverse effects 
(proarrhythmogenic side effects) of 
antiarrhythmic drugs 
 
DPD 
(dihydropyrimidine  
dehydrogenase) 
TPMT 
(thiopurine S-methyl-
transferase) 
Fluorouracil 
 
 
6-Mercaptopurine, thioguanine, 
azathioprine 
 
Fluorouracil neurotoxicity  
 
 
Thiopurine hematotoxicity and 
efficacy, risk of secondary cancers 
ACE 
(angiotensin converting 
enzyme) 
Drug targets 
Enalapril, lisinopril, captopril   
Renoprotective effects, cardiac  
indices, blood pressure 
immunoglobulin A nephropathy 
 
Potassium channels: 
 
HERG   
  
 
 Quinidine    
 
 Cisapride 
 
 
Drug-induced long QT syndrome 
Drug-induced torsade de pointes 
KvLQT1 Terfenadine, disopyramide,  
Mefloquine 
Drug-induced long QT syndrome 
hKCNE2   Clarithromycin Drug-induced arrhythmia 
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1.4 Genetic variability 
 
The frequently studie metabolizing enzymes are the cytochrome P450 (CYP450) isoenzymes, 
the N-acetyltransferase (NAT) isoenzymes, the UDP glucuro-nosyl transferase, and the 
methyltransferase. Of these enzymes, the CYP450s are very important because they meta-
bolize drugs into products that are readily excreted into the urine and faeces. In humans, six 
different forms of CYP P450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and 
CYP3A4) are largely responsible for eliminating drugs. The rate of metabolism by several of 
the cytochrome CYP450 enzyme subfamilies varies, due to genetically determined polymer-
phisms in all population studied. Recent research using  phenotyping and genotyping 
techniques has reflected the interest and importance of these pharmacogenetic factors in 
determining drugs responses (Emilien et al., 2000). By inhibiting cytochrome P450, one drug 
can impair the biotransformation of another drug. Such drug-drug interactions can lead to an 
excessive pharmacological or toxicological response to the second drug. In this regard, 
inhibition of cytochrome P450 mimics the effects of a genetic deficiency in P450 enzyme 
expression. Increased P450 enzyme activity can result from (1) gene duplication leading to 
overexpression of a P450 enzyme, (2) exposure to environmental factors, such as xenobiotics, 
that induce the synthesis of cytochrome P450, or (3) stimulation of a pre-existing enzyme by a 
xenobiotic. By inducing cytochrome P450 one drug can stimulate the metabolism of a second 
drug and thereby decrease or increase its therapeutic effect. A dramatic effect of this type of 
drug interaction is the induction of ethinylestradiol metabolism by phenobarbital and rifampin, 
which can decrease the contraceptive effect of the former drug and lead to pregnancy 
(Breckenridge et al., 1980). Allelic variants, which arise from point mutations in the wild-type 
gene, are another source of interindividual variation in P450 activity. Amino acid substitution 
can increase or, more commonly, decrease P450 enzyme activity, although the effect may be 
substrate-dependent. Some of the genetic factors that influence P450 activity identified thus 
far are summarized (Nagata and Yamazoe, 2002), http://www.imm.ki.se/CYPalleles). 
 The environmental factors which are known to affect P450 expression include medications 
(e.g. barbiturates, rifampin, isoniazid), food (e.g. cruciferous vegetables, charcoal broiled 
beef), social habits (e.g. alcohol consumption, cigarette smoking), and disease status (diabetes, 
inflammation, hyperthyroidism and hypothyroidism). When environmental factors influence 
P450 enzyme levels, a considerable variation may be observed when xenobiotic bio-
transformation (e.g. drug metabolism) is measured repeatedly in the same individual.  
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The variation in therapeutic response to warfarin treatment due to CYP2C9 polymorphism 
(Furuya et al., 1995; Steward et al., 1997; Aithal et al., 1999) is an example of pharmaco-
kinetics. Another essential aspect of pharmacokinetics is drug absorption. (Hoffmeyer et al., 
2000) have demonstrated that polymorphisms in the multidrug- resistence gene-1 influence 
digoxin absorption. The current use and future perspectives of molecular genetic characterisa-
tion of cytochrome P450 enzymes (CYP) for drugs development and drug treatment are 
summarised. CYP genes are highly polymorphic and the enzymes play a key role in the 
elimination of the majority of drugs from the human body. 
 
1.4.1 Genetic variability in drug metabolism 
 
In different people and different population, activity of cytochrome P450 enzyme differs. 
Genetic variation in a population is termed polymorphism when both gene variants exist with 
a frequency of at least one percent. Such differences in activity may have profound clinical 
consequences, especially when multiple drugs are given to a patient (Cupp and Tracy, 1998). 
The explanation for the  various polymorphisms are thought to be complex, but perhaps the 
most interesting is the high expression of CYP2D6 in many persons of Ethiopian and  
Arabian origin. CYP2D6 is not inducible, so these people have developed a different strategy 
to cope with the (presumed) high load of toxic alkaloids in their diet- multiple copies of the 
gene. These CYPs therefore chew up a variety of drugs, making them ineffective - many 
antidepressants and neuroleptics are important examples. Conversely prodrugs will be exten-
sively activated from example codeine will be turned in vast amounts into morphine. 
(Ingelman-Sundberg et al., 1999). 
1.4.2  CYP2D6 genetic variability 
 
At least 30 drugs, many of them derived from plant alkaloids, have subsequently been shown 
to be oxidized by CYP2D6, including tricyclic antidepressants, some neuroleptics, beta- 
blokers, and antiarrhythmic agents such as perhexiline, flecainide, and encainide. Several  
drugs of abuse including codeine (Chen et al., 1988), hydroquinone (Otton et al., 1993), 
dextromethorphan (Schmid et al., 1985), and p-methoxyamphetamine (PMA) (Kitchen et al., 
1979) are known to be metabolized by this enzyme.  
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CYP2D6 polymorphisms are clinically important mainly  because of the greater likelihood of 
adverse reactions among persons with poor metabolism, because of the high plasma 
concentration of the affected drug, and lack of efficacy among persons with ultra rapid 
metabolism, owing to the consequently low plasma concentration of the affected drug. 
Because genotyping has not been performed in most people, the response to particular drugs 
is usually unanticipated. For example, increased cardiovascular toxicity is more likely after 
usual doses of venlafaxine, a selective serotonin- reuptake inhibitor and adverse effects of 
tricyclic antidepressants are more frequent in persons with poor metabolism than in those with 
extensive metabolism. Similarly, persons with poor metabolism have a greater risk of adverse 
effects when taking metoprolol than do persons with other types of metabolism. The use of 
typical antipsychotic agents had been observed to induce various adverse effects. One of the 
most serious effects is tardive dyskinesia (TD). TD is an involuntary movement disorder 
characterized by a variable combination of orofacial and lingual dyskinesia, tics, grimacing 
and choreoathetoid hyperkinetic movements in trunk and limbs (Woerner et al., 1991). 
Several risk factors for TD have been identified. The most important predictors of TD include 
older age, female gender, organic brain disorders, cigarette smoking, diabetes mellitus and 
total exposure to antipsychotic drugs (Casey, 1999). Influences of the exposure to typical 
neuroleptics on TD include the duration of antipsychotic treatment (Casey, 1991; Casey, 
1999), and the dosage of antipsychotic medications (Casey, 1991; Casey, 1999). TD 
occurrence appears to be correlated with higher antipsychotic dosage and consequently, with 
the plasma level of the drugs (Casey, 1995; Tugg et al., 1997). Therefore, factors that may 
contribute to a high antipsychotic plasma level might confer the risk of TD. Most typical 
antipsychotics are in part metabolized by the cytochrome P-450 2D6 (CYP2D6) (Bertilsson et 
al., 1993; Jerling et al., 1996). Four phenotypes have been identified according to the 
metabolic activity of CYP2D6: extensive metabolizers, intermediate metabolizers, poor 
metabolizers (PM) and ultra rapid metabolizers (Sachse et al., 1997; Garcia-Barcelo et al., 
2000). The various enzymatic activities and phenotypes of CYP2D6 are encoded by genetic 
polymorphisms (Andreassen et al., 1997; Armstrong et al., 1997). Several studies had 
evaluated the relationships between PM genotypes of deficient alleles (CYP2D6*3, 
CYP2D6*4 and CYP2D6*5) on the CYP2D6 gene and the TD occurrence in a Caucasian 
population. Nevertheless, their conclusion remained controversial (Armstrong et al., 1997; 
Ellingrod et al., 2002).  
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In addition, the incidence rate of the PM phenotype in Chinese or Japanese subjects is lower 
than in white patients (1% and 5– 10 %, respectively) (Bertilsson et al., 1992) and the 
deficient CYP2D6*3 and CYP2D6*4 alleles, which code the PM phenotype, are rare in 
Chinese subjects (Garcia-Barcelo et al., 2000). However, early studies showed that the 
enzymatic activity of CYP2D6 is lower in the Oriental compared with the Caucasian 
population (Bertilsson et al., 1992). Wang et al. identified a defective allele, CYP2D6*10, 
which resulted from C188T substitution, that may be accounted for the lower CYP2D6 
activity in Orientals (Wang et al., 1993). Ohmori et al. (Ohmori et al., 1998) revealed a trend 
association between CYP2D6*10 genotypes and TD, and a significant correlation between 
genotypes and total Abnormal Involuntary Movement Scale (AIMS) scores.  
1.4.3 CYP2C19 genetic variability 
 
CYP2C19 is a clinically important enzyme which metabolizes a wide variety of drugs, such 
as the anti-convulsant mephenytoin (Wilkinson et al., 1989). Anti-ulcer drugs such as 
omeprazole (Andersson et al., 1992), certain antidepressants (Sindrup et al., 1993a) and 
(Baumann et al., 1986), the anti malarial proguanil (Ward et al., 1991) and the anxiolytic 
drugs diazepam . It is also partially responsible for the metabolism of a number of other drugs, 
such as the β-blocker propranolol metabolism of these drugs in-vivo is polymorphic in 
humans. Individuals can be characterized as extensive metabolizers or poor metabolizers of 
drugs metabolized by CYP2C19 in population studies. Poor metabolizers  represent 2-5 % of 
Caucasians, 13- 23 % of Asian populations and as many as 38- 79 % of individuals of some 
of the islands of Polynesia and Micronesia (Kaneko et al., 1999). African population have 
been studied less extensively, but the poor metabolizer trait has been reported  to be 
approximately 40% in African- Americans from mid- Tennessee (Edeki et al., 1996), Africans 
from Zimbabwe and Nigerians (Daniel and Edeki, 1996). Poor metabolizers can experience 
undesirable side- effects, such as prolonged sedation and unconsciousness after administration 
of diazepam. This can be a particular problem in Asian patients where the poor metabolizer 
phenotype is frequent. In contrast, omeprazole has been reported to produce a greater cure 
rate for gastric ulcers and accompanying Helicobacter pylori infections in CYP2C19 poor 
metabolizers than in extensive metabolizers because blood levels are higher in these 
individuals (Goldstein, 2001). For CYP2C19, 16 allelic variants have been identified 
http://www.imm.ki.se/CYPallele. 
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CYP2C19*2 and CYP2C19*3 are important, since the CYP2C19*2 allelic variant accounted 
for 75– 83 % of the poor metabolizer (PM) phenotypes in Caucasian (De Morais et al., 1994) 
and Asian populations (de Morais et al., 1994). Furthermore, CYP2C19*2 and *3 combined, 
accounted for 100 % of PM phenotypes in a study of a Japanese population (Ibeanu et al., 
1998). CYP2C19*2 variant causes a 681G>A nucleotide change in exon 5 that creates a 
splicing defect, and CYP2C19*3 is a 636G>A change that generates a stopcodon in exon 4. 
The distr ibution http://www.imm.ki.se-/CYPallele, (De Morais et al., 1994; de Morais et al., 
1994),  of these allelic variants within different ethnic groups varies. For instance, Asian 
populations exhibit higher allelic frequencies of CYP2C19*2 (21– 45%) and CYP2C19*3 (2– 
16%) (Roh et al., 1996; Kimura et al., 1998Roh, 1996 #119)) than European-American 
populations ( *2: 13–19%; *3: 0– 0.3%) (Goldstein et al., 1997; Ruas and Lechner, 1997; Xie 
et al., 1999). By contrast, CYP2C9*2 and CYP2C9*3 appear to be more prevalent in 
European and American populations (8– 15%; 5– 16%) (Yasar et al., 1999) than in Asian 
populations (0; 1– 5%) (Sullivan-Klose et al., 1996, Kimura, 1998 #118, Nasu, 1997 
#125,{Yoon, 2001 #126). Although the genetic polymorphism of the CYP2C subfamily has 
been widely studied, there are no data regarding South American populations. Its population 
is divided ethnically into three main groups: the Amerindian (55 %), Mestizo (30 %) and 
White (15 %) people. The Amerindian population is represented by approximately 35 ethnic 
groups, which are clustered based on their linguistic characteristics. The Arawak (mojo), 
Aymara, Chiquitano, Mataco- Mac’a, Pano, Quechua, Tacana, Tupi-Guarani and Uru- 
Chipaya are the major ethno- linguistic groups of theAmerindian group. The Mestizo 
population is the admixture between White and Amerindian populations. This admixture is 
explained in part by the historical (Aklillu et al., 2003) events of the Spanish Conquest in the 
Americas that produced a mixture between mostly Quechua and Spaniards. The White 
population represents a small proportion of the population. In addition to the arrival of the 
Spaniards during the Spanish Conquest, a significant number of Europeans immigrated to 
Boliviabe fore and during World War II. http://www.ine.gov.bo.   
 
1.4.4 CYP1A2 genetic variability 
 
CYP1A2, a hepatic enzyme inducible by smoking, metabolizes various chemical procar-
cinogens, such as food- derived heterocyclic and aromatic mutagens, N- heterocyclics found 
in tobacco smoke, and difuranocoumarins, to reactive carcinogens (McManus et al., 1990). 
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 It is also involved in the metabolism of several drugs such as paracetamol, theophylline, 
caffeine, and clozapine (Bertilsson et al., 1994). Endogenous substrates of CYP1A2 include 
estradiol and uroporphyrinogen. The enzyme has a significant role in chemical carcino-
genesis (Eaton et al., 1995) and is induced by its substrates, and a polymorphism in its 
capacity to activate procarcinogens has been indicated (Minchin et al., 1985). Hepatocellular 
carcinoma is a common neoplasm, especially in Africa, and is to a great extent caused by the 
intake of dietary aflatoxin (Uwaifo and Bababunmi, 1984). CYP1A2 has been reported to play 
a more important role than CYP3A4 in the bioactivation of aflatoxin at low concentrations in 
human liver microsomes (Gallagher et al., 1996). The antiparasitic drug oltipraz, which is 
currently on phase- II human clinical trials for its cancer- chemopreventive effect in humans, 
especially with respect to aflatoxin- associated hepatocarcinogenesis, has been shown to be a 
potent inhibitor of CYP1A2 (Sofowora et al., 2001). Subjects with higher CYP1A2 activity 
and exposed to dietary aflatoxin B1 might  be at a higher risk for developing hepatocellular 
carcinoma. Individual differences in CYP1A2 activity may thus influence individual 
susceptibility to cancer and the therapeutic efficacy of some drugs. The human CYP1A2 gene, 
located on chromosome 15, spans about 7.8 kb and contains seven exons. The coding region 
starts at nucleotide 10 of exon 2 (Ikeya et al., 1989). Exon 2- 6 is highly conserved among 
human, mouse, and rat. In these species, regions of high conservation have also been found in 
intron 1 of CYP1A2 (Ikeya et al., 1989) suggesting a possible regulatory role of this intron. 
Two single-nucleotide polymorphic sites (SNPs), –164G>A and –740T>G, have previously 
been reported in the intron 1 of human CYP1A2 gene  http://www.imm.ki.se-/CYPalleles-
/CYP1a2.htm. The – 164C>A SNP has been suggested to be associated with higher enzyme 
inducibility by smoking among white persons (Sachse et al., 1997), whereas the – 740T>G 
has not been functionally characterized.  Previous studies on the human CYP1A2 gene 
regulation in HepG2 cells have identified two regions of importance for basal expression: a 
proximal region containing a GC box, a CCAAT box and a TATA box, and a distal region, 
named "1A2 enhancer," which contains two activator protein-1 sites, a xenobiotic- responsive 
element, and a hepatic nuclear factor 1 site and a second TATA box) (Quattrochi et al., 1994; 
Chung and Bresnick, 1995; Chung and Bresnick, 1997). The aryl hydrocarbon receptor null 
mice show significant decrease in CYP1A2 expression in the liver, suggesting that the 
xenobiotic-responsive elements may be involved in the regulation of the basal expression 
(Schmidt et al., 1996).  
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It is possible that several of these factors, including nuclear factor 1, participate in the tissue- 
selective activation of CYP1A2 gene expression and that the absence of any single component 
may abolish or down- regulate gene expression. The human CYP1A subfamily consists of 
CYP1A1 and CYP1A2. The former is expressed mainly in extra hepatic tissues, and the latter 
is almost exclusively expressed in the liver. CYP1A2 is responsible for the oxidative 
metabolism of drugs such as theophylline, mexiletine, and phenacetin (Distlerath et al., 1985; 
Sarkar and Jackson, 1994; Nakajima et al., 1998). This enzyme has also been shown to be 
involved in the metabolic activation of carcinogenic arylamines to produce reactive 
intermediates (Eaton et al., 1995). Up to 60-fold inter-individual variation in the CYP1A2 
activity has been reported (Shimada et al., 1994; Saruwatari et al., 2002). Also, approximately 
15- and 40- fold interindividual variations in CYP1A2 mRNA and protein expression levels 
have been observed in the human liver (Ikeya et al., 1989; Guengerich et al., 1999). These 
interindividual differences are likely to influence the drug metabolism and to be associated 
with drug efficacy and safety and cancer susceptibility caused by procarcinogens. 
Environmental factors have been thought to influence the interindividual differences. Cigarette 
smoking and intake of oral contraceptive steroids are well established modifiers of CYP1A2 
activity (Rasmussen et al., 2002). However, it has been suggested that approximately 35 to 75 
% of the interindividual variability in CYP1A2 activity is due to genetic factors (Kendler and 
Prescott, 1999; Rasmussen et al., 2002). Since CYP1A2 is inducible by environmental factors, 
many investigators have tried to identify single nucleotide polymorphisms (SNPs) in the 
transcriptional regulatory regions: the distal enhancer region, the promoter region, noncoding 
exon 1, and intron 1. CYP1A2*1C (–3860G>A) was reported to be associated with decreased 
enzyme inducibility in Japanese smokers (Nakajima et al., 1999). CYP1A2*1F (–163C>A), 
located in intron 1, has been suggested to be linked with a higher enzyme inducibility in white 
smokers (Sachse et al., 1999). Recently, Aklillu et al. reported that the CYP1A2*1K haplotype 
(–739T>G, –729C>T, and –163C>A; all in intron 1) was associated with decreased enzyme 
activity in Ethiopian non smokers. As for the coding exons, Phe21Leu (CYP1A2*2) was first 
reported from the direct sequencing of DNA from one of eight Chinese subjects (Huang et al., 
1999). The other four nonsynonymous SNPs (Asp348Asn, CYP1A2*3; Ile386Phe, *4; 
Cys406Tyr, *5; and Arg431Trp, *6), found in French whites, were reported to alter protein 
expression levels and/or alter enzymatic activities depending on the substrates  (Zhou et al., 
2004).  
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1.5 Investigated known and presumed substrates of cytochrome P450 enzymes 
1.5.1 Analgesic-antipyretic drugs 
 
The anti-inflammotory, analgesic and antipyretic drugs are a heterogeneous group of 
compounds, often chemically unrelated (although most of them are organic acids), which 
nevertheless share certain therapeutic actions and side effects. The prototypes are aspirin, 
metamizole and aminopyrine. Hence these compounds are often referred to as aspirin-like 
drugs they also are frequently called nonsteroidal anti-inflammatory drugs, or NSAIDs, an 
abbrivation that is used throughout this thesis when refering to these agents. There has been 
substantial progress in elucidating mechanism of action of NSAIDs. Inhibition of 
cyclooxygenase (COX), the enzyme responsible for the biosynthesis of the prostaglandins and 
certain related autacoids, generally is thought to be a major facet of mechanism of NSAIDs. 
Some of shared properties of NSAIDs are considered first. then the more important drugs are 
discussed in some detail. 
 
1.5.2  Mechanism of action of NSAIDs 
 
Although NSAIDs had been known to inhibit a wide variety of reactions in-vitro, no 
convincing relationship could be established with their known anti- inflammatory, antipyretic, 
and analgesic effects until 1971, when Vane and associates and Smith and Willis 
demonstrated that low concentration of aspirin and indomethacin inhibited the enzymatic 
production of prostaglandins. There was, at that time, some evidence that prostaglandins 
participated in the pathogenesis of inflammation and fever, and this reinforced the hypothesis 
that inhibition of the biosynthesis of these autacoids could explain  a number of the clinical 
action of the drugs (Higgs and Vane, 1983). Numerous subsequent observations have 
reinforced this point of view, including the observation that prostaglandins are released 
whenever cells are damaged, they appear in inflammatory exudates, and NSAIDs inhibit the 
biosynthesis of prostaglandins in all cells tested. However, NSAIDs generally do not inhibit 
the formation of eicosanoids such as the leukotrienes, which also contribute to inflammation, 
nor do they affect the synthesis of numerous other inflammatory mediation. There are 
differences of opinion as to whether or not NSAIDs may have other actions that contribute to 
their therapeutic effects. 
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1.5.3 Metamizole  
 
Metamizole, or dipyrone, chemically [(2,3-dihydro-1,5 dimethyl-3-oxo-2-phenyl-1H-pyrazol-
4-yl) me-thylamino] methanesulphonic acid, is an effective and widely used drug in several 
countries because of its analgesic and antipyretic properties (Agundez et al., 1994). 
Metamizole was first synthesized by the German company Hoechst AG in 1920, and its mass 
production started in 1922. Metamizole is a pyrazoline derivative available in oral and 
parenteral forms acting as inhibitor of cyclooxygenases. It has been used as a  nonsteroidal 
anti-inflammatory agent (Bonkowsky et al., 2002) as well as a potent analgesic and 
antipyretic drug in many countries for more than 60 years. Oral doses of 0.5 to 1 g (Pereira et 
al., 1985) are effective in treating fever. Repeated doses (up to 4 times daily) can be 
administered, the maximum recommended dose is 3 to 4 g daily (Sadusk, 1965). Metamizole 
is given orally as capsules or at tablets. Sometimes, users of metamizole prefer to swallow the 
contents of an ampoule for parenteral administration, because they believe that the analgesic 
effect is quicker than with the usual solid oral forms (Artaza et al., 2002). However, 
metamizole has been associated with fatal agranulocytosis and was withdrawn from the US 
market in 1979 (Bonkowsky et al., 2002). The complex metabolism of metamizole has been 
the subject of many in-vivo studies (Levy et al., 1995). In the pharmacokinetics of metamizole, 
the specific CYP catalyzing the formation of the primary metabolic step to the active 
metabolite 4-aminoantipyrine (4-AA) is still not known. The biotransformation pathway of 
metamizole (Levy, 1986) and (Artaza et al., 2002)  is well established. It is nonenzymatically 
dealkylated in the gastric juice to the active moiety 4-methylaminoantipyrine (4-MAA) 
(Ergun et al., 2004; Vlahov et al., 1990). 4-MAA undergoes demethylation in the liver to 4-
aminoantipyrine (4-AA) (Brune and Otterness, 1988; Flusser et al., 1988). AA undergoes 
further phase-II biotransformation to acetyl-aminoanipyrine (AAA) by the polymorphic N-
acetyltransferase (Fig. 3). Metamizole was developed in times where specific CYP enzymes 
were not yet known but knowledge of the relevant specific CYP enzymes may help in 
predicting drug- drug interactions. It may also help in elucidating the relevant bioactivation 
reactions which in some persons result in agranulocytosis. 
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Fig. 3  Structure and biotransformation of metamizole and its main metabolites in man, drawn according 
to (Geisslinger et al., 1996). 
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1.5.4 Aminopyrine 
 
Aminopyrine or amidopyrine, chemically 4-(dimethylamino)-1,2 dihydro-1,5-dimethyl-2-
phenyl-3H-pyrazol-3-one, played a key role in the in-vivo study of human hepatic drug 
metabolism, because it was widely used as a probe of liver function (Rodzynek et al., 1986; 
Lane, 1988) and enzymatically active hepatocellular mass (Krahenbuhl et al., 1989; Agundez 
et al., 1994) in several diseases such as liver cirrhosis (Urbain et al., 1990), chronic hepatitis 
(Lashner et al., 1988), hepatocarcinoma (Feuer, 1988), or liver ischemia (Metzger and 
Lauterburg, 1988). Aminopyrine also called amidopyrine, pyrazolone, 4-dimethyl-
aminoantipyrine or antipyrine, is a pyrazolone-class analgesic agent used in otic solution 
(solution for treatment of ear deseases) in combination with other analgesic drugs such as 
benzocaine, and phenylephrine (Agundez et al., 1995). Aminopyrine is a five-membered 
lactam ring compound containing two nitrogens and ketone in the same molecule. The lactam 
structure is an active nucleus regarding pharmacological activity. Aminopyrine may be a 
useful addition to  pharmaceutical ingredients, especially to the class of non-steroidal anti-
inflammatory agents used in the treatment of arthritis and other musculoskeletal and joint 
disorders. Pyrazolone derivatives are also widely used in preparing dyes and pigments has 
recently been restricted in several countries for human use because of its potential side effects, 
including mutagenicity (Norkus and Kuenzig, 1985) and agranulocytosis. However, 
aminopyrine and derivatives, such as dipyrone, are still used in Europe as analgesic drugs. 
The use of this drug as an indicator for enzymatic activity of the liver after hepatic 
transplantation has been proposed (Okland et al., 1989). Microsomal cytochrome P450 
dependent aminopyrine N-demethylation has been widely studied in rat liver microsomes 
(Henderson et al., 1986; Imaoka et al., 1988), rabbit intestinal mucosa (Ichihara et al., 1983; 
Kaku et al., 1985) and rabbit liver (Johnson and Muller-Eberhard, 1977), bovine liver 
(Tsubaki and Ichikawa, 1985), monkeys (Kastner et al., 1989) and other animal models as 
well as in humans (Sharonov Iu et al., 1986; Imaoka et al., 1990). The metabolic pathways 
involved in human disposition of aminopyrine and metamizole have been elucidated, and the 
involvement of demethylation, formylation and acetylation pathways has been shown in man 
( Fig. 4) (Brodie et al., 1950; Iguchi et al., 1975; Noda et al., 1976; Volz and Kellner, 1980).  
The potential side- effects of aminopyrine and metamizole may be related to interindvidual 
variation in the metabolism of such drugs. 
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Fig. 4  Structure and biotransformation of aminopyrine and its main metabolites in man, according to  
(Agundez et al., 1994) 
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Fig. 5  Structure and biotransformation of aminopyrine and metamizole and their main metabolites in 
man, according to (Agundez et al., 1994) 
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2 AIMS OF THE STUDY 
The aims of this thesis were to investigate which specific cytochrome P450 enzymes are 
involved in the biotransformation of the analgesic-antipyretic drugs metamizole and 
aminopyrine. Such knowledge should help to understand bioactivation mechanisms which 
may be related to the toxicity of these drugs and such knowledge should also help to 
understand drug-drug interactions and to understand which genetic polymorphisms might play 
a role in metamizole or aminopyrine. The analgesic drug metamizole (dipyrone) is non-
enzymatically hydrolyzed to 4-methylaminoantipyrine making this the substance of primary 
interest in our project. In this context, four specific questions should be answered: 
 
1. For the metamizole project, firstly an HPLC assay should be developed and 
optimized to allow quantification of 4-methylaminoantipyrine and 4-aminoantipyrine 
in incubation solutions with rat or human liver microsomes or with heterologously 
expressed specific human cytochrome P450 enzymes. These assays should firstly be 
optimized based on incubations with rat liver microsomes before going on with human 
enzymes. 
 
2. Enzyme kinetics of cytochrome P450 mediated metabolism of 4-methyl-
aminoantipyrine should then be analyzed with rat liver microsomes, with human liver 
microsomes from different donors without and with specific inhibitors which should 
help to identify the relevant enzymes. These results should be confirmed by 
incubations with heterologously expressed specific human cytochrome P450 enzymes. 
All data should be analyzed by linearization using Lineweaver and Burk plots and by 
nonlinear regression analysis. 
 
3. For the aminopyrine project, accordingly an HPLC assay should be developed 
and optimized to allow quantification of dimethylaminoantipyrine (synonyms: 
antipyrine, aminopyrine, amidopyrine) and its primary metabolite methylamin-
oantipyrine in microsomal incubations. 
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4. Enzyme kinetics of cytochrome P450 mediated metabolism of dimethyl-
aminoantipyrine should then be analyzed with rat liver microsomes, with human liver 
microsomes from different donors without and with specific inhibitors which should help 
to identify the relevant enzymes. These results should be confirmed by incubations with 
heterologously expressed specific human cytochrome P450 enzymes. All data should be 
analyzed by linearization using Michaelis-Menten equation and by nonlinear regression 
analysis. 
Materials and Methods 
 
 
 27
3  MATERIALS AND METHODS 
 
Biotransformation was studied in the subcellular fraction termed microsomes, which is a fraction of 
membrane vesicles corresponding to the endoplasmic reticulum in the intact cell. Microsomes were 
isolated from rat and human liver tissues. The impact of genetic polymorphism in one of the 
enzymes apparently involved in biotransformation of the studied drugs, CYP2C19, was analyzed in 
the used human liver samples by allelic discrimination. The microsomes were incubated with the 
substrates metamizole and aminopyrine, respectively. The produced metabolites were identified and 
quantified using HPLC analysis. Enzyme kinetic data analysis was finally used to determine enzyme 
kinetic parameters. More specific details about the material and assays used during this 
investigations are described within this section. 
 
3.1  Materials 
3.1.1  Instruments 
 
Instruments Manufacturer 
HPLC pump L-7100 Merck, Darmstadt, Germany 
HPLC pump L-600 A Merck Hitachi, Tokyo, Japan 
HPLC autosampler L-7200 Merck, Darmstadt, Germany 
HPLC autosampler 655-40 A Merck Hitachi, Tokyo, Japan 
HPLC ultraviolet detector L-7400 Merck, Darmstadt, Germany 
HPLC ultraviolet detector 655-A Merck Hitachi, Tokyo, Japan 
Biophotometer (Instrument designed for 
analysis of DNA, RNA, Oligonucleotide and 
Proteins) 
Eppendorf, Hamburg, Germany 
Centrifuge-5810 Eppendorf, Hamburg, Germany 
Ultracentrifuge LB-70M Beckman, Palo Alto, USA 
Ultracentrifuge J2-21M/E Beckman, Palo Alto, USA 
Ultracentrifuge T-2190 Centricon, Milano, Italy 
Balances Sartorius AG, Göttingen, Germany 
pH Meter Knick, Berlin, Germany 
pH Meter CG 822 Ikamag, Hofheim, Germany 
Water bath (for microsomal incubation) Kötterman, Uetze, Germany 
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Evaporation thermo-Dux Techne, Cambridge, UK 
Tecan Ultra (Microtiter plate fluorimeter) Tecan, Crailsheim,Germany 
Bio robot (Instrument designed for automating 
DNA isolation using a solid phase extraction 
method) 
Qiagen, Hilden, Germany 
GLF  Bi-Dest 2104 Multilab, Düsseldorf, Germany 
 
3.1.2  Consumable materials 
 
Products Manufacturer 
Adhesive PCR film ABgene, Hamburg, Germany 
Adhesive PCR foil seals ABgene, Hamburg, Germany 
Cuvette Eppendorf, Hamburg, Germany 
Tubes 15 ml Greiner, Flacht, Germany 
Tubes 50 ml Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Tubes 1.5 ml with cap Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Tubes 2.0 ml wich cap Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Reaction tubes Eppendorf, Hamburg, Germany 
Nitrile examination gloves Ansell, München, Germany 
Latex gloves Kimberley-Clark, Koblenz, Germany 
Cytostatic gloves Berner International, Elmshorn, Germany 
Pre-column for HPLC Merck, Darmstadt, Germany 
Lichrospher 100 RP-8e column (5 µm particle 
size, 125 x 4.6 mm inner column dimensions) 
Merck, Darmstadt, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Pipettes with filter Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Disposable plastic  Pipettes Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Centrifuge tubes (20 x 89 mm) Beckman, Palo-Alto, USA 
HPLC caps GL45 Merck, Darmstadt, Germany 
HPLC vials Merck, Darmstadt, Germany 
HPLC Lamp Merck, Darmstadt, Germany 
HPLC strips of cap Merck, Darmatadt,Germany 
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3.1.3  Chemicals 
 
Chemicals Manufacturer 
4-aminoantipyrine Sigma chemical, Steinheim, Germany 
Aminopyrine Sigma chemical, Steinheim, Germany 
Metamizole Synopharm, Barsbüttel, Germany 
Methylaminoantipyrine Sigma chemical, Steinheim, Germany 
Formylaminoantipyrine Sigma chemical, Steinheim, Germany 
Ketoconazole Sigma chemical, Steinheim, Germany 
Alpha-naphthoflavone Sigma chemical, Steinheim, Germany 
Omeprazole Sigma chemical, Steinheim, Germany 
Moclobemide Sigma chemical, Steinheim, Germany 
Sulphaphenazole Sigma chemical, Steinheim, Germany 
Coumarin Fluka, Steinheim, Germany 
Quinidine Fluka, Steinheim, Germany 
Furafylline 
Prof. Dr. Fuhr. University of Cologne, 
Germany 
Fluvoxamine Synthon, Nigmegen, Netherlands 
Tranylcypromine Röhm Pharma, Weiterstadt, Germany 
NADPH Roche, Mannheim, Germany 
NaCl Appli Chem, Darmstadt, Germany 
Protein standard (BSA) Biorad, Hercules (CA, USA) 
Potassium dihydrogen phosphate Merck, Darmstadt, Germany 
Ampli Tag TM DNA polymerase Applied Biosystems, Foster city, USA 
Potassium hydroxide pellets Merck, Darmstadt, Germany 
di-sodium hydrogen phosphate Merck, Darmstadt, Germany 
Ortho- phosphoric acid Merck, Darmstadt, Germany 
Sucrose Merck, Darmstadt, Germany 
Pefabloc SC (protease inhibitor, 4-(2-
aminoethyl)-benzenesulfonyl fluoride 
hydrochloride) 
Roche, Mannheim, Germany 
Ammonium acetate Merck, Darmstadt, Germany 
Taq DNA polymerase Qiagen, Hilden, Germany 
Taq Man universal PCR master mix Applied Biosystems, Foster city, USA 
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Tris base Applied Chem, Darmstadt, Germany 
EDTA Merck, Darmstadt, Germany 
HCl Merck, Darmstadt, Germany 
Bromphenol blue Roth, Karlsruhe, Germany 
Glycerine Roth, Karlsruhe, Germany 
 
3.1.4  Kits/Reagents 
Reagents Manufacturer 
Bradford protein assay Biorad, München, Germany 
 
3.1.5  Solvents 
Solvents Manufacturer 
Acetonitril pro analysis Merck, Darmstadt, Germany 
Methanol pro analysis Merck, Darmstadt, Germany 
Acetonitril pro analysis J.T. Baker, Deventer, Holland 
Methanol pro analysis J.T. Baker, Deventer, Holland 
Double distilled water 
Labaratories of the department of Clinical 
pharmacology, Göttingen University 
Ethanol pro analysis J.T. Baker, Deventer, Holland 
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3.1.6  Drug metabolizing enzymes 
 
Materials Type Manufacturer 
Human liver samples HL001 
HL003 
HL009 
HL010 
HL014 
HL016 
 
Department of Clinical 
Pharmacology University, 
Göttingen, Germany 
Rat liver samples RLM 001 
RLM 002 
Department of 
Toxicology, University 
Göttingen, Germany 
Pooled human liver 
microsomes 
 
HLM Natutec, Frankfurt am 
Main, Germany 
Recombinant human 
CYP450 enzymes 
CYP1A1 
CYP1A2 
CYP1B1 
CYP2A6 
CYP2B6 
CYP2E1 
CYP2C8 
CYP2C9*1 
CYP2C19 
CYP3A4 
CYP3A5 
CYP3A7 
CYP2D6 
Natutec, Frankfurt am 
Main, Germany 
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3.2 Methods  
3.2.1 In-vitro metabolism 
3.2.1.1 Human and rat liver samples 
 
The seven samples of human liver used in the metamizole and aminopyrine study were 
obtained from a liver bank at the Department of Clinical Pharmacology, Georg-August 
University in Göttingen, Germany. The donors were white Europeans. The liver samples 
included nontumorous tissue surrounding primary liver tumors or metastases of various 
tumors or liver tissues surgically removed for other reasons. The samples of rat liver from 
male Wistar rats weighing between 180 to 220 g, aged 3 months were kindly provided by the 
Department of Toxicology at the University of Göttingen. 
 
3.2.1.1.1 Preparation of Human liver microsomes 
 
Human hepatic microsomes (HLM) were prepared by subcellular fractionation as described 
previously (Pearce et al., 1996). Liver tissue was put into homogenization buffer (20 mM Tris 
pH 7.4 at 4°C, 5 mM sodium EDTA, 254 mM sucrose, 0.2 mM 4-(2-aminoethyl)-
benzolsulfonylfluoride (Pefabloc SC) in an ice bath, liver tissue was weighted, minced with 
scissors, mixed in a proportion of 1 g tissue in 4 ml buffer, homogenized subsequently with an 
ultraturax homogenizer at 9,500 rpm for 30 seconds three times, and subsequently 
homogenized with a Potter-Elvehjem (Glass tube) tissue grinder with 5 to 10 strokes at 1000 
rpm.  
The obtained homogenate was centrifuged by 3000 g for 30 minutes in an Eppendorf 5810 R 
centrifuge. The supernatant was removed and centrifuged by 17000 g for 30 minutes at +2°C 
in a J2-21 M/E Beckman centrifuge. Then the obtained supernatant was removed and 
centrifuged at 100000 g (29,000 rpm) for 60 minutes in a Beckman Ti50.2 rotor at + 4°C in a 
L8-70 M Beckman ultracentrifuge. The resulting supernatant (the cytosolic fraction) was 
removed and stored at -80 °C (not used in the experiments of this project). The resulting pellet 
(human liver microsomes) was resuspended in microsomal buffer (20 mM Tris, pH 7.4, at 4°C, 
5 mM sodium EDTA, 254 mM sucrose and 30% glycerol v/v) and homogenized with a Potter-
Elvehjem tissue grider at 1000 rpm. The microsomes were then aliquoted and stored at -80°C 
until use. The rat liver microsomes  were prepared at the same procedures described for 
human liver microsomes. 
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3.2.1.1.2 Protein quantification 
 
The protein quantity in microsomal preparations was assessed using the Bradford method 
(Bradford, 1976) which is based on the observation that the absorbance maximum for an 
acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when 
binding to protein occurs. Both hydrophobic and ionic interactions stabilize the anionic from 
of the dye, causing a visible color change. The test samples for blank, BSA standards and the 
protein samples to be tested (unknown samples) were generated. The concentration of protein 
standards (BSA) ranged from 2 to 20 µg /µl. The dye reagent (1:5 diluted in deionised water) 
was added to the samples which were then allowed to incubate for 15 min. Thereafter, each 
sample was measured at 595 nm using a UV-visible spectrophotometer (Bio photometer). The 
absorbance of BSA standard was plotted as a linear function of its theoretical concentration (Y 
= m x + b, where Y = absorbance at 595 nm and x = protein concentration) according to the 
Beer-Lambet law. Using this equation, the protein concentration of each unknown protein 
samples was calculated based on their measured absorbance. 
 
3.2.2 In-vitro incubation 
3.2.2.1 Metamizole 
 
The in-vitro microsomal incubation of metamizole was conducted as described in the 
following experimental protocol (Table 4). Precisely, stock solutions of 4-methyl-
aminoantipyrine ranging from 0.5 to 1.0 mM were prepared in methanol. Volume of these 
stock solutions representing one of six concentration levels (25, 50, 100, 400, 800 and 1200 
µmo/l) were evaporated under a stream of nitrogen for 10 min. The residue was then 
redissolved in 50 µl of 50 mM potassium phosphate buffer (pH 7.4). Recombinant human 
CYP450 enzymes, HLM or RLM pre-diluted in the same phosphate buffer were added in a 
volume 25 µl following a previously described method (Evert et al., 1997). The reaction (total 
volume 100 µl) was initiated by the addition of 25 µl of 10 mM NADPH, dissolved freshly in 
the same incubation buffer, and allowed to proceed for 10 to 20 min at 37°C in opened 
Eppendorf tubes in a shaking water bath. In some experiments, the incubation mixture was 
adjusted to a final volume 200 µl.  
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The incubations consisted of (final concentration given) 50 mM potassium phosphate buffer 
(pH 7.4), BE cytochrome P450 (0.4 - 0.6 pmol/ µl), HLM and RLM (5 - 10 mg protein /ml), 2 
mM NADPH and 25 to 1200 µmol/l  4-methylaminoantipyrine in a final volume of 100 µl. 
The reactions were stopped by adding ice-cold acetonitrile (100 µl). The resulting mixture 
was centrifuged at 13000 rpm for 5 min. 100 µl of the supernatant were used for HPLC 
analysis. The formation of 4-aminoantipyrine was linear with time between 6 and 10 min. 
 
 
Table 4 In-vitro microsomal incubation (example of an experimental protocol) 
Analysis of 4-methylaminoantipyrine metabolism by HLM without inhibitors 
 
 
4-methylaminoantipyrine final concentration in 100 µl incubation volume 
 25 µM 50 µM 100 µM 400 µM 800 µM 1200 µM 
4-MAA 0.5 mM in methanol (µl) 10 20 40    
4-MAA 1.0 mM in methanol (µl)    80 160 240 
Methanol (µl) 230 220 200 160 80 0 
Evaporation  / N2 37 °C  (min) 10 10 10 10 10 10 
Addition of phosphate buffer (µl) 50 50 50 50 50 50 
Pre- incubation (min) 5 5 5 5 5 5 
Addition of human liver microsomal 
solution 10 mg /ml phosphate buffer 
(µl) 
25 25 25 25 25 25 
Pre-incubation (min) 10 10 10 10 10 10 
Addition of 10 mM NADPH  (µl) 25 25 25 25 25 25 
Incubation in opened Eppendorf   
Tubes (min) 20 20 20 20 20 20 
Addition of ice-cold acetonitrile (µl) 
 100 100 100 100 100 100 
Centrifugation at 14000 rpm (min) 5 5 5 5 5 5 
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3.2.2.1.1 Determination of inhibition characteristics. 
 
The 4-methylaminoantipyrine was incubated for 20 min together with the selective chemical 
inhibitors ketoconazole (CYP3A4), alpha-naphthoflavone (CYP1A1), coumarin (CYP2A6), 
omeprazole (CYP2C19), quinidine (CYP2D6), tranylcypromine (CYP2C19), fluvoxamine 
(CYP1A2 and CYP2C19), furafylline (CYP1A2), moclobemide (CYP2C19) and (CYP2D6) 
and sulphaphenazole (CYP2C9). The inhibitors were dissolved in methanol or water. The 
concentrations of the inhibitors were 50, 100, 500 µM. Aminopyrine was incubated together 
with selective chemical inhibitors moclobemide, coumarin, ketoconazole, alpha-
naphthoflavone, furafylline and quinidine at the same procedures described for 4-
methylaminoantipyrine.  
 
Table 5 Experimental protocol of measuring methylaminoantipyrine metabolism by HLM with inhibitors 
4-methylaminoantipyrine final concentration in 100 µl incubation volume 
 25 µM 50 µM 100 µM 400 µM 800 µM 1200 µM 
4-MAA 0.5 mM in methanol (µl) 10 20 40    
4-MAA 1.0 mM in methanol (µl)    80 160 240 
Addition of inhibitor (µl)  solution*  50 50 50 50 50 50 
Methanol  (µl) 230 220 200 160 80 0 
Evaporation  / N2 37 °C  (min) 15 15 15 15 15 15 
Addition of phosphate buffer (µl) 50 50 50 50 50 50 
Pre-incubation (min) 5 5 5 5 5 5 
Addition of human liver microsomal 
solution 10 mg /ml phos phate buffer 
(µl) 
25 25 25 25 25 25 
Pre-incubation (min) 10 10 10 10 10 10 
Addition of 10 mM NADPH  (µl) 25 25 25 25 25 25 
Incubation in opened Eppendorf   
Tubes (min) 
20 20 20 20 20 20 
Addition of ice cold acetonitrile (µl) 
 
100 100 100 100 100 100 
Centrifugation at 14000 rpm (min) 5 5 5 5 5 5 
*The inhibitors were prepared as two solutions: solution1 with 100 µ M of the inhibitors and solution 2 with 1 
mM of the inhibitors. For 50 µM final inhibitor concentration, 50µl from solution 1, for 100 µM a 100 µl from 
solution 1 and for 500 µM a 50 µl from solution 2 were added.  
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3.2.2.1.2  Incubations with heterologously expressed isolated human CYP450s  
 
The recombinant human CYP450 enzymes, pre-diluted in the 50 mM potassium phosphate 
buffer (pH 7.4), were added in a volume of 25 µl following a previously described method 
(Evert et al., 1997). The reaction (total volume 100 µl) was initiated by the addition of 25 µl 
of 10 mM NADPH, dissolved freshly in the same incubation buffer, and allowed to proceed 
for 20 min at 37°C in opened Eppendorf tubes in a shaking water bath as shown in Table 6. 
 
Table 6 Experimental protocol of the incubations of methylaminoantipyrine with heterologously expressed 
CYP450 enzymes 
 
 
4-methylaminoantipyrine final concentration in 100 µl incubation volume 
 
25 µM 50 µM 100 µM 400 µM 800 µM 1200 µM 
4-MAA 0.5 mM in methanol (µl) 10 20 40    
4-MAA 1.0 mM in methanol (µl)    80 160 240 
Methanol (µl) 230 220 200 160 80 0 
Evaporation  / N2 37 °C  (min) 10 10 10 10 10 10 
Addition of phosphate buffer (µl) 50 50 50 50 50 50 
Pre- incubation (min) 5 5 5 5 5 5 
Addition of CYP450 solution 0.6 
pmol/µl  in phosphate buffer (µl) 
25 25 25 25 25 25 
Pre-incubation (min) 10 10 10 10 10 10 
Addition of 10 mM NADPH  (µl) 25 25 25 25 25 25 
Incubation in opened Eppendorf   
Tubes (min) 
20 20 20 20 20 20 
Addition of ice cold acetonitrile (µl) 
 
100 100 100 100 100 100 
Centrifugation at 14000 rpm (min) 5 5 5 5 5 5 
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3.2.2.2  Aminopyrine 
 
Stock solutions of aminopyrine (ranging from 0.5 to 1.0 µM) were prepared in methanol and 
were allowed to evaporate under N2 as in the following experimental protocol (Table 7). 
Aminopyrine was then dissolved in 50 µl of 50 mM potassium phosphate buffer (pH 7.4). The 
final incubation volume was 100 µL. The end concentration of aminopyrine ranged from 25 to 
1200 µM. The recombinant cytochrome P450 enzymes or the HLM were added to the reaction 
mixture in a volume of 25 µl prior to the start of the reaction with NADPH, following a 
previously described method  (Evert et al., 1997) and allowed to proceed for 20 min at 37°C 
in opened Eppendorf tubes in a shaking water bath, and stopped by the addition of 100 µl ice-
cold methanol containing 25 µM sulphaphenazole as an internal standard. The incubation 
mixtures were then centrifuged at 10000 g for 5 min. Supernatants were transferred into new 
tubes and 100 µl were used for the HPLC analysis. The formation 4-methylaminoantipyrine 
was linear with time between 4 and 10 min and with protein ranging from 10 mg/ml for HLM 
and from 0.6 pmol for baculovirus-expressed cytochromes. The substrate consumption was 
<10 % over the incubation time (20 min). 
 
3.2.2.2.1 Determination of inhibition characteristics 
 
The 4-dimethylaminoantipyrine was incubated for 20 min together with the selective chemical 
inhibitors ketoconazole (CYP3A4), alpha-naphthoflavone (CYP1A1), coumarin (CYP2A6), 
quinidine (CYP2D6), furafylline (CYP1A2), and moclobemide (CYP2C19 and CYP2D6). 
The inhibitors were dissolved in methanol or water. The concentrations of the inhibitors were 
50, 100, 500 µmol/l as described in the above experimental at the procedures described for 
methylaminoantipyrine (Table 5). 
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Table 7 In-vitro microsomal incubations (example of experimental protocol) of dimethylaminoantipyrine 
with HLM.  
 
4-Dimethylaminoantipyrine final concentration in 100 µl incubation volume 
 25 µM 50 µM 100 µM 400 µM 800 µM 1200 µM 
4-DMAA 0.5 mM in methanol (µl) 10 20 40    
4-DMAA 1.0 mM in methanol (µl)    80 160 240 
Methanol (µl) 230 220 200 160 80 0 
Evaporation  / N2 37 °C  (min) 10 10 10 10 10 10 
Addition of phosphate buffer (µl) 50 50 50 50 50 50 
Pre-incubation (min) 5 5 5 5 5 5 
Addition of human liver microsomal 
solution 10 mg /ml phosphate buffer 
(µl) 
 
25 25 25 25 25 25 
Pre-incubation (min) 10 10 10 10 10 10 
Addition of 10 mM NADPH  (µl) 25 25 25 25 25 25 
Incubation in opened Eppendorf   
tubes (min) 
 
20 20 20 20 20 20 
Addition of ice cold acetonitrile (µl) 
 
100 100 100 100 100 100 
Centrifugation at 14000 rpm (min) 5 5 5 5 5 5 
 
The in-vitro incubations with chemical inhibitors and with heterologously expressed isolated 
cytochrome P450 enzymes was conducted as described in the table above and as described for 
metamizole. 
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3.2.3  HPLC analysis and chromatographic conditions 
3.2.3.1  Metamizole 
 
HPLC for analysis of metamizole and metamizole metabolites was performed similar as 
described earlier (Asmardi and Jamali, 1983; Geisslinger et al., 1996). The incubation 
mixtures were centrifuged at 14000 rpm for 5 min. Supernatants were transferred into new 
tubes and 100 µl used for HPLC analysis. The HPLC system consisted of a L-600A pump 
(Merck, Hitachi Tokyo, Japan) and 655A-40 autosampler (Merck, Hitachi Tokyo, Japan). The 
system was equipped with a LiChrospher 100 (Å pore size) RP-8e select column with 5 µm 
particle size (Merck, Darmstadt, Germany) with internal dimensions of 4 mm x 125 mm 
preceded by a pre-column (100 Å, diol coated, 5 µM particle size) and some experiments 
were on a HPLC system consisting of a L-7100 pump (Merck, Darmstadt, Germany) and L-
7200 autosampler (Merck, Darmstadt, Germany). The system was equipped with a 
LiChrospher 100 RP-8e select column 5 µm particle size (Merck, Darmstadt, Germany) 
preceded by a pre-column (100 Diol, 5 µM). The mobile phase consisted of 75 % (v/v) of 50 
mM sodium phosphate buffer (pH 6.0) and 25% (v/v) methanol. The flow rate was 1.0 ml/min. 
The absorbance was measured at 254 nm with an ultraviolet (UV) detector (655 A Merck 
Hitachi Tokyo, Japan) linked to computer data system. The injection volume in these analyses 
was 40 µl, and the retention times of 4-methylaminoantipyrine (4-MAA), 4-aminoantipyrine 
(4-AA), and internal standard 4-dimethylaminoantipyrine (4-DMAA) were 10.30, 7.70 and 
16.75 minutes, respectively. 
 
3.2.3.2  Aminopyrine 
 
The HPLC system consisted of a L-600A pump (Merck, Hitachi Tokyo, Japan) and 655A- 40 
auto sampler (Merck, Hitachi Tokyo, Japan). The system was equipped with LiChrospher 100 
RP-8e select column (5 µm particle size, 100 Å pore size, 4 x 125 mm internal dimensions; 
Merck, Darmstadt, Germany) preceded by a pre-column (100 Diol, 5 µM). The mobile phase 
consisted of 80 % ( v/v) of 50 mM sodium phosphate buffer (pH 6.0), acetonitrile 19 % ( v/v) 
and 1 % ( v/v) methanol. The flow rate was 1.0 ml/min. The absorbance was measured at 254 
nm, linked to computer data system with an ultraviolet (UV) detector (655 A Merck Hitachi 
Tokyo, Japan). The injection volume in these analyses was 40 µl, and the retention times of 4-
methylaminoantipyrine (4-MAA), 4-dimethylamino-antipyrine (4-DMAA), and internal 
standard sulphaphenazole were 6.00, 7.70 and 9.60 minutes, respectively.  
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3.3 Data analysis 
3.3.1 Software  
 
Table 8  Computer programs applied 
 
 
 
Table 9  Electronic Databases used in this dissertation 
 
 
 
 
 
Software Application Source    
HPLC integration software 
AIDA software 
Signal quantification Merck, Darmstadt, Germany 
Excel 2002 (Microsoft 
Office)   
Linear regression analysis 
and other statistical 
calculations 
 
Microsoft, Redmont, WA, 
USA 
Sigma Plot  S/PW 9.0 Nonlinear regression 
Michaelis-Menten enzyme 
kinetic analysis (Km Vmax) 
 
Chicago, IL, USA 
Regress 3. EXE  Linear regression Dr. Meineke, Clinical 
Pharmacology  University, 
Göttingen, Germany 
Database URL 
Directory of P450- Containing Systems http:// WWW.icgeb.trieste.it 
Drugs Metabolized by Cytochrome P450 http://WWW.georgetown.edu/departments/pha
rmacology/clinlist.html 
Pubmed (NIH) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
Cytochrome P450 Allele Nomenclature http://www.cypalleles.ki.se 
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3.3.1.1 Calculations and estimation of enzyme kinetic parameters 
3.3.1.2 Metamizole 
3.3.1.2.1 Calculation of metamizole concentrations from the HPLC chromatograms 
 
Concentrations of 4-MAA formation in the incubation samples were calculated by the aid of 
calibration samples (calibration range: 1 – 10 µg/ml). Peaks of the substances to be measured 
(S) were electronically integrated and the ratio of the Peak area of S over the peak area of the 
internal standard (4-dimethylaminoantipyrine) was plotted against the standard concentrations. 
Regession analyses for these calibrations were performed with the programm regress3.exe. 
 
Table 10  Table with calibration data from one series of AA analysis. 
Concentration 
µg/ml 
Peak area 
4-MAA 
Peak area 
4-AA 
Peak area 
IS 
4-MAA 
µg/ml 
4-AA 
µg/ml 
1 105 107 2461 1.00 1.00 
2 392 384 2467 1.96 1.96 
5 1021 1034 2524 4.98 5.15 
10 1982 1861 2467 10.12 9.83 
 
 
3.3.1.2.2  Calculation of enzyme kinetic constants Vmax and KM 
 
From the HPLC-quantified 4-AA the formation rate (pmol / mg / min) was calculated  The 
formation rates corresponding to the six substrate concentrations (see incubation conditions 
above) were then subjected to a regression analysis in order to estimate KM and Vmax 
according to the Michaelis-Menten equation by nonlinear regression analysis with the 
programm SigmaPlot. 
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3.3.1.2.3  Determination of the IC50 and Ki for the Inhibition 
 
 The Ki was determinated by Sigma plot 9.0 and the IC50 were determinated with 50 µM of 4-
methylaminantipyrine incubated at 37 °C for 20 min with different concentration of inhi-
bitors. The IC50 values were then calculated with the equation of (Naritomi et al., 2003). 
 
 
3.3.1.3  Aminopyrine 
 
3.3.1.3.1   Calculation of 4-DMAA concentrations from the HPLC analyses 
 
Concentrations of 4-DMAA formation in the incubation samples were calculated by the aid of 
calibration samples (calibration range: 1 – 10 µg/ml). Peaks of the substances to be measured 
(S) were electronically integrated and the ratio of the Peak area of S over the peak area of the 
internal standard (sulphaphenazole) was plotted against the standard concentrations. 
Regession analyses for these calibrations were performed with the programm regress3.exe. 
 
Table 11 Table with calibration data from one series of AA analysis. 
Concentration 
µg/ml 
Peak area 
MAA 
Peak area 4-
4-DMAA 
Peak area  
IS 
MAA  
µg/ml 
DMAA  
µg/ml 
1 105 60 1653 1.00 1.04 
2 392 142 1587 1.96 1.81 
5 1021 922 1592 4.98 5.12 
10 1982 2037 1620 10.12 10.31 
 
 
 
3.3.1.3.2  Calculation of enzyme kinetic constants Vmax and KM 
 
From the quantified 4-MAA the formation rate (pmol/ mg protein / min) was obtained. The 
formation rates corresponding to the six substrate concentrations were then subjected to a 
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regression analysis in order to estimate KM and Vmax according to the Michaelis-Menten 
equation. The Michaelis-Menten equation is given in the following formula where V 
representes the velocity of product formation and [S] the respective substrate concentrations: 
][
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3.3.2.2.3 IC50 and Ki for the Inhibition 
 
 
These constants were analysed for aminopyrine and for metamizole in the same manner. For 
analysis of the inhibition constant (Ki) and the concentration of the inhibitor resulting in 50% 
inhibition (IC50), the Cheng and Prusoff equation was used as follows: 
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3.3.2 Predication of pharmacokinetic clearance  
 
The enzyme kinetic parameters of recombinant human CYP450 enzymes and human liver 
microsomal were used to estimate the in-vitro intrinsic clearance for the reaction from 4-
methylaminoantipyrine to 4-aminoantipyrine and for the reaction from 4-
dimethylaminoantipyrine to 4-methylaminoantipyrine. The intrinsic clearance was calculated 
at CLint =Vmax / Km  (Houston, 1994; Naritomi et al., 2003).  
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3.4  Method validation 
3.4.1   Incubation 
3.4.1.1  Solubility 
 
 
All investigated substances were dissolved in the buffer under the concentration ranges used. 
Some chemical inhibitors were dissolved in methanol. Control experiments detected >92 % of 
the substrates (4-methylaminoantipyrine and 4-dimethylaminoantipyrine) in the buffer 
following incubation at 37 °C. 
 
 
3.4.1.2  Standard curves 
 
Standard curves were obtained by injecting the extracts of microsomes from one liver without 
NADPH generating system and with NADPH but zero incubation time, standard peak were 
obtained by injecting  1, 2, 5, 10 µg /ml  from reference substrates and peak area ratios 
relative to the internal standard were plotted verus concentrations of the standard.  
 
3.4.2  HPLC analysis 
 
3.4.2.1  Limit of detection (limit of quantification) 
 
The limit of detection was 0.25, 0.031, and 0.015 µg/ml of 4-dimethylaminoantipyrine, 4- 
methyl-aminoantipyrine and 4-aminoantipyrine respectively and the limit of quantification 
was 1 µg/ml for all three substances. The retention time of chemical inhibitors (to document 
exclusion of interference with the analysis of 4-methylaminoantipyrine and 4-
dimethylaminoantipyrine was 15.20 for furafylline. The other chemical inhibitors did not 
show any signal within the range of retention time considered for this analysis.  
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3.4.2.2  Intra-day variability (inter-day variability) 
 
The intra-assay coefficient (inter- assay coefficient) of variation was determined by measuring 
the formation of the produced targeted metabolite in a series of n (ranging from 15 to 20) 
identical incubation on the same day (different days) using aliquots of the same HLM lot. The 
intra-assay coefficient of variation for the formation of 4-aminoantipyrine was 5.5%. The  
inter- day coefficient of variation for the formation of 4-aminoantipyrine was 6.5%. The intra-
assay coefficient of variation for the formation of 4-methylaminoantipyrine was 5.5 %. The 
inter-day coefficient of variation for the formation of 4-methylaminoantipyrine (4-MAA) was 
13.8 %.  
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4 RESULTS 
4.1 Investigations of the metabolism of metamizole by RLM 
HPLC Analysis. The substances 4-aminoantipyrine (4-AA) (peak 1, Fig. 6) and 4-
methylaminoantipyrine (4-MAA) (peak 2) have been measured with HPLC as illustrated in a 
chromatogram obtained from injection of 20 µl of standard solution with 25 µmol/l of 4-AA 
and 4-MAA, each. As shown in the figure, the separation was completed within 10 min. The 
retention times were 5.08 min for 4-AA and 6.72 min for 4-MAA (Fig. 6). 
 
 
                         
Fig. 6  Typical chromatogram of the main metabolites of metamizole obtained from standard samples of 
reference substance. Peaks: AA (5.08 min), MAA (6.72 min).  The mobile phase consisted of 80 % of 50 
mM sodium phosphate buffer (pH 6. 0), 15% acetonitrile  and 5% methanol degassed before use, and the 
flow rate was 1. 0 ml/min. Stationary phase was a reversed phase (RP) octylsilane endcapped (5 µm 
particle size, 125 ҳ 4 mm internal dimensions ) column equipped with a pre-column (diol-coated, 5 µm 
particle size). 
 
 
Incubation of 4-methylaminoantipyrine with all microsomal preparations resulted in the 
formation of the 4-aminoantipyrine as the only detectable metabolite of 4-methyl-amino-
antipyrine as shown in Fig. 7.  
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Fig. 7   Elution profiles of 4-methylaminoantipyrine and its metabolites by HPLC with a RP-8 endcapped 
(5 µm particle size, 125 ҳ 4 mm internal dimensions) column equipped with a pre-column (100 Å pore size, 
diol-coated, 5 µm particle size). The mobile phase consisted of 80 % (v/v) of 25 mM sodium phosphate 
buffer (pH 6.0), 15% acetonitrile and 5% (v/v) methanol. The flow rate was 1.0 ml/min. The absorbance 
was measured at 254 nm with a detector linked to a computer data system. The chromatogram shows 4-
methylaminoantipyrine and its metabolite formed by rat liver microsomes. A reaction mixture (200 µl) 
with 1.25 mg/ml (final concentration) of microsomal protein from male Wistar rats, 1.0 mg/ml of NADPH 
and 50 µmol of 4-methylaminoantipyrine was incubated for 20 min at 37 °C in 25 mM potassium 
phosphate buffer (pH 7.4). 4-methylaminoantipyrine metabolites were extracted and analyzed by HPLC. 
Peaks: 4-AA at 5.15 min and 4-MAA at 6.78 min. 
 
 
Two different preparations of rat liver microsomes were used. Mean Vmax (arithmetic mean of 
5 incubations) was 201 pmol/min (standard deviation, SD, 42.2 pmol/min) and mean KM was 
20.9 µmol/l (SD 3.8) as shown in Fig. 8. The corresponding intrinsic clearance was 9.61 
µl/min (SD 3.9). The quantity of microsomal protein was 0.250 mg protein in each assay. 
HPLC chromatograms from incubations of the metamizole metabolite 4-
methylaminoantipyrine with hepatic microsomes of untreated male Wistar rats weighing 
between 180 to 220 g, aged 3 months and  two control incubation samples without NADPH 
and zero incubation time are shown in (Fig. 9) right and left respectively.  
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Fig. 8 Kinetic plot of demethylation of 4-methylaminoantipyrine by RLM. The reaction mixture (200 µl ) 
included 1.25 mg/ml (final concentration) of microsomal protein of male Wistar rats and 1.0 mg/ml of 
NADPH. 4-methylaminoantipyrine was incubated for 20 min at 37 °C in 25 mM potassium phosphate 
buffer (pH 7.4). 4-methylaminoantipyrine metabolites were extracted and analyzed by HPLC. 
 
Fig. 9 (Right ) Chromatogram of an extract from rat liver microsomes obtained after 20 min incubation of 
MAA without NADPH. Peaks: MAA at 6.76 min. (Left ) Extract from rat liver microsomes obtained 0 
min after incubation with MAA. The metabolite was not seen in the right and left by HPLC with a RP-8 
endcapped (5 µm partical size; 125 ҳ 4 mm internal dimensions) column equipped with a pre-column (100 
Å pore size, diol-coated, 5 µM particle size). The mobile phase consisted of 80 % (v/v) of 50 mM sodium 
phosphate buffer (pH 6.0), 15% acetonitrile and 5% (v/v) methanol. The flow rate was 1.0 ml/min.  The 
absorbance was measured at 254 nm with a UV detector linked to computer data system. chromatogram 
of 4-methylaminoantipyrine (4-MAA) metabolites by microsomes. A reaction mixture (200 µl) including 
1.25 mg/ml of microsomal protein of male wistar rats and 50 µmol of 4-methylaminoantipyrine was 
incubated for 20 min at 37 °C in 25 mM potassium phosphate buffer, (pH 7.4). 4-Methylaminoantipyrine 
metabolites were extracted and analyzed by HPLC. 
4-methylaminoantipyrine (50 µM) was incubated with rat liver microsomes (5 mg/ml of 
microsomal protein) at 37 °C for 20 min and the metabolites were analyzed by HPLC after 
extraction. No metabolites were seen when 4-methylaminoantipyrine and microsomes were 
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incubated without NADPH and with NADPH but without any incubation time (0 min). In rat 
liver microsomes, the metabolism of 4-methyaminoantipyrine was strongly inhibited by a 
concentration of 50 µM omeprazole as shown in Fig. 10, the inhibition was (65 % inhibition) 
and to a lesser degree by ketoconazole (37 % inhibition) and but no inhibition was detected 
with alpha-naphthoflavone, coumarin, quinidine and sulphaphenazole as shown in Table 12.  
Table 12 Estimated % inhibition of the formation of 4-aminoantipyrine by selective chemical inhibitors 
added at a concentration of 50 µM. A reaction mixture (200 µl), 5 mg/ml of microsomal protein of male 
Wistar rats, and 50 µmol of 4-methylaminoantipyrine was incubated for 20 min at 37°C in 25 mM 
potassium phosphate buffer, ( pH 7.4) 4-methylaminoantipyrine metabolites were extracted and analyzed 
by HPLC. 
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Fig. 10 Inhibition kinetic plot of metabolism of MAA with RLM by omeprazole. The reaction mixture 
(200 µl), contained 1.25 mg/ml of microsomal protein of male Wistar rats and 1. 0 mg/ml of NADPH. 4-
methylaminoantipyrine was incubated for 20 min at 37 °C with 50 µM omeprazole in 25 mM potassium 
phosphate buffer, (pH 7.4). 4-methylaminoantipyrine metabolites were extracted and analyzed by HPLC. 
 
RLM 
Inhibitors % Inhibition Ki  (mM) IC50 (mM) 
Omeprazole 65.90 0.04 0.05 
Ketoconazole 36.60 0.14 0.77 
Sulphaphenazole (no inhibition) - - 
Coumarin (no inhibition) - - 
Quinidine (no inhibition) - - 
Alpha-naphthoflavone (no inhibition) - - 
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4.2   Investigations of the metabolism of metamizole by HLM  
 
HPLC Analysis. Typical chromatograms obtained from reference substances of 4-
aminoantipyrine (4-AA, peak 1) and methylaminoantipyrine (4-MAA, peak 2) obtained after 
injection of 10 µmol from AA and MAA into the HPLC system are illustrated in Fig. 11. The 
separation was complete within 20 min. The retention time of 4-AA was 7.70 min, the 
retention time of 4-MAA was 11.30 min and that of the internal standard (I.S., 
dimethylaminoantipyrine) was 16.75 min. 
 
Fig. 11  Typical chromatogram of the main metabolites of metamizole obtained from standard samples. 
Peaks: 1: 4-AA at 7.70 min, peak 2: MAA at 11.30 min, peak 3: I.S  at 16.75 min. The concentrations of 4-
MAA and 4-AA were 10 µmol/l. The mobile phase consisted of 75 % (v/v) of 25 mM sodium phosphate 
buffer (pH 6.0) and 25% (v/v) methanol. The flow rate was 1.0 ml/min. 
 
The formation of 4-aminoantipyrine from 4-methylaminoantipyrine in the human liver 
microsomes increased in a protein-concentration and time-dependent manner. The metabolism 
of 4-methylaminoantipyrine was analyzed in seven preparations of human liver microsomes 
(HLM) with an incubation time of 20 min, and two control incubation samples, one without 
NADPH and one with zero incubation time.  
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4-Methylaminoantipyrine was incubated with human liver microsomes (2.5 mg/ml of 
microsomal protein, final concentration, at 37 °C) for 20 min and the metabolites were 
analyzed by HPLC after extraction. No metabolites were seen when 4-methylaminoantipyrine 
and microsomes were incubated without NADPH and also not if incubated with NADPH but 
with an incubation time of zero. The formation was linear at to 10 mg/ml microsomal protein 
and 20-min incubation time. The formation of 4-aminoantipyrine from 4-methyl-
aminoantipyrine by one preparation of human liver microsomes is illustrated in a 
chromatogram in Fig. 12 and in dependence from substrate concentration in Fig. 13. 
 
Fig. 12  HPLC-analysis of an extract of 4-methylaminoantipyrine and its metabolites after incubation with 
human liver microsomes. HPLC was performed with a RP-8 endcapped (5 µm) (125 ҳ 4 mm) column 
equipped with a pre-column (100 Diol, 5 µM). The mobile phase consisted of 75 %(v/v) of 25 mM sodium 
phosphate buffer (pH 6.0) and 25%(v/v) methanol. The flow rate was 1.0 ml/min. The absorbance was 
measured at 254 nm with an UV detector linked to a computer data system. A reaction mixture (100 µl; 
2.5 mg/ml of microsomal protein of HLM) with 1.0 mg/ml of NADPH, and 100 µmo/l of 4-methylamino-
antipyrine was incubated for 20 min at 37°C in 50 mM potassium phosphate buffer (pH 7.4). 4-
methylaminoantipyrine metabolites were extracted and analyzed by HPLC. Peaks: AA at 7.73 min, MAA 
at 11.23 min, I.S. at 16.59 min. 
 
A maximum biotransformation rate (Vmax) of 143 (standard deviation 30) pmol/min/mg was 
measured. The quantity of microsomes protein in one sample was 2.5 mg protein. The mean 
Michaelis-Menten constant (KM) was 154 µmol/l with a standard deviation of 40 µmol/l as 
shown in Fig. 13. The intrinsic clearance was 0.92 µl/min/mg.  
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Table 13 Enzyme kinetic parameters for metamizole demethylation by human liver microsomes. The 
metamizole concentration ranged from 25 to 800 µmol/l. The protein concentration of HLM protein was 
10 mg/ml. 
Preparation KM (µM) Vmax 
(pmol/min/mg 
microsomal 
protein) 
Intrinsic 
clearance 
HL008 154 143 0.92 
HL 001 251 144 0.57 
HL 009 201 163 0.81 
HL 010 289 147 0.51 
HL 003 152 312 2.05 
HL 014 228 111 0.49 
Mean (standard deviation) from  
the 6 preparations given above 
213 (54.4) 170 (71.6) 0.89 (0.59) 
Liver withouth CYP2C19 (genotype *2/*2) 
HL 016 477 166 0.34 
All parameters from the 7 microsomal preparations given above were derived from 
measurements performed in duplicates for each substrate concentration. 
 
In the chemical inhibition study with human liver microsomes an inhibitory effect on 4-
methylaminoantipyrine N-demethylation was seen for fluvoxamine as illustrated in Fig. 12. In 
Table 14 further data are given showing that inhibition occurred also from co-incubation with 
omeprazole, moclobemide and tranylcypromine. Other selective inhibitors had smaller effects 
on the metabolism of metamizole in microsomal incubation (Fig. 15).  
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Fig. 13  Plot of the substrate concentration versus metabolite formation rate for demethylation of 4-
methylaminoantipyrine by human liver microsomal preparation HLM008. The reaction mixtures (100 µl) 
with 2.5 mg/ml of microsomal protein, 1.0 mg/ml of NADPH. and 4-methylaminoantipyrine were 
incubated for 20 min at 37 °C in 25 mM potassium phosphate buffer (pH 7.4). 4-methylaminoantipyrine 
metabolites were extracted and analyzed by HPLC. 
 
Table 14  Inhibition effects of inhibitors on 4-aminoantipyrine formation from methylaminoantipyrine. 
Extract from human liver microsomes obtained 20 min after incubation with 4-MAA 50 µmol/l with 50 
µM from chemical inhibitors was monitored by HPLC analysis. Results are presented as average of 
duplicate incubations. 
HLM 
Inhibitors % Inhibition* Ki (mM) IC50 (mM) 
 
Fluvoxamine 
 
57.12 
 
0.06 0.07 
Omeprazole 51.09 0.06 0.07 
Tranylcypromine 50.32 0.15 0.18 
Moclobemide 43.24 0.66 0.79 
Coumarin 31.86 1.20 1.44 
Sulphaphenazole 25.06 1.31 1.54 
Ketoconazole 27.95 1.45 1.86 
Alpha-naphthoflavone 18.65 3.90 4.68 
Furafylline 16.09 4.01 5.41 
Quinidine 11.35 6.88 8.46 
* % inhibition refers to the inhibition produced by co-incubation of 50 µM 4-MAA with 50 µM of the 
various inhibitors compared with the incubations without inhibitor. 
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Fig. 14 Illustration of the concentration-dependent inhibition of the metabolism of 4-MAA by fluvoxamine. 
The reaction mixtures (100 µl) included 2.5 mg/ml of microsomal protein, 1.0 mg/ml of NADPH and 4-
methylaminoantipyrine in the concentrations given in the figure as well as fluvoxamine in concentrations 
of 0, 50, 100 and 500 µM and it was incubated for 20 min at 37 °C in 25 mM potassium phosphate buffer 
(pH 7.4).  
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Fig. 15  Inhibition of the metabolism of 4-dimethylaminoantipyrine by characteristic inhibitors of specific 
CYP enzyme. Extract from human liver microsomes obtained 20 min after incubation with 4-MAA 50 µM 
with 50 µM from chemical inhibitors was monitored by HPLC analysis. Results are presented as average 
of duplicate incubations. The detailed numbers are given in Table 14. 
 
 
 
 
 
 
 
The metabolism of 4-methylaminoantipyrine was inhibited by 57.21, 51.09 and 50.32% by a 
concentration of 50 µmol/l of the known CYP2C19 inhibitors fluvoxamine, omeprazole and 
tranylcypromine with Ki values of 0.06, 0.06 and 0.15 mM respectively.  
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Fig. 16  Extract of 4-methylaminoantipyrine and its metabolites by HPLC with a RP-8 endcapped (5 µm) 
(125 ҳ 4 mm) column equipped with a pre- column (100 Diol, 5 µM). The mobile phase consisted of 75 % 
( v/v) of 25 mM sodium phosphate buffer (pH 6.0) and 25 %( v/v) methanol. The flow rate was 1.0 ml/min. 
The absorbance was measured at 254 nm with an UV detector linked to computer data system. The  
chromatogram shows 4-methylaminoantipyrine metabolites formed by the microsomes. A reaction 
mixture (100 µl ) 2.5 mg/ml of microsomal CYP2C19 genotype (*2/*2) protein of HLM,  1.0 mg/ml of 
NADPH, and 200 µmol of 4-methylaminoantipyrine was incubated for 20 min at °37 in 50 mM potassium 
phosphate buffer, (pH 7.4.) 4-methylaminoantipyrine metabolites were extracted and analyzed by HPLC. 
Peaks: AA (8.00 min), MAA (11.77 min), I.S. (17.56 min). 
 
 
 
The corresponding IC50 values were 0.07, 0.07 and 0.18 mM respectively. The IC50 values 
seen with coumarin, sulphaphenazole, ketoconazole, moclobemide, quinidine, alpha-naphtho-
flavone and furafylline were: 0.79, 1.20, 1.36, 1.44, 3.46, 4.68, and 8.41 mM and the ki values 
were 0.66, 1.00, 1.13, 1.20, 2.88, 3.90 and 7.01 mM respectively (Table 14). These chemical 
inhibition data suggested that CYP2C19 was primarily responsible for the metabolism of 4-
methylaminoantipyrine. The production of AA by microsomes CYP2C19 genotype (*2/*2, 
meaning expression of not any CYP2C19 enzyme) was very low as illustrated in the 
following HPLC chromatogramn (Fig. 16). As summarized in Table 13, mean KM for 4-
MAA demethylation of microsomes expressing CYP2C19 was 213 µM (standard deviation 
54.4) compared with 477 µM in the microsomes of a subject deficient in CYP2C19. 
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4.3 Investigations of the metabolism of metamizole by recombinant Human 
CYP 
 
The enzymes kinetics of metabolism of 4-metylaminoantipyrine were finally studied by 
recombinant Human specific human CYP enzymes to confirm the specific CYP enzyme 
involved in biotransformation of 4-methyl-aminoantipyrine, which appeared to be the enzyme 
CYP2C19 according to the inhibition study and according to one experiment with human 
liver microsomes from a CYP2C19 deficient subject. Microsomes carrying only specific 
individual recombinant human cytochrome P450 isozymes (CYP1A1, CYP1B1, CYP1A2, 
CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and 
CYP3A7) were incubated with different concentrations of 4-MAA from 25 to 800 µmol/l in 
the presence of an NADPH-regenerating system at 37°C for 20 min. The substrate 4-
methylaminoantipyrine was converted into 4-aminoantipyrine by all cytochrome P450 
isoenzyme praparations when tested at high substrate concentration. The enzyme kinetic 
constants are given in (Table 15). Thus, some formation of 4-AA was observed in the 
incubations with CYP1A1, CYP1B1, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP3A7, whereas the high formation of 4-AA 
was observed only with CYP2C19 and with CYP1A2, data are given in Fig. 17, 18 and 19 
respectively.  
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Fig. 17  Cytochrome P450 isozymes active in the in-vitro demethylation of 4-methylaminoantipyrine. 4-
MAA was incubated with microsomes expressing human recombinant P450 isozymes (0.6 pmol/µl) for 20 
min and the concentrations of 4-methylaminoantipyrine were 25, 50, 100, 400, 800 µmol/l. The formation 
of 4-aminantipyrine AA was monitored by HPLC analysis with UV detection. Results are given as means 
of duplicate incubations. 
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The formation rates of 4-aminoantipyrine (AA) with rCYP2C19 were faster than with the 
other P450 isozymes. Also, the highest catalytic efficiency (intrinsic clearance, Vmax/Km) was 
observed with CYP2C19, (0.077 µl/min/pmol). 
 
Michaelis-Menten
[Substrate] (µM)
0 200 400 600 800 1000 1200 1400
R
at
e 
(p
m
ol
/p
m
ol
 C
Y
P/
m
in
)
0
2
4
6
8
10
 
Fig. 18  Kinetic plot of demethylation of 4-methylaminoantipyrine by recombinant Human CYP2C19 
enzyme. MAA was incubated with human recombinant CYP2C19 enzymes (0.6 pmol/µl) for 20 min and 
the concentrations of 4-methyaminoantipyrine were 25, 50, 100, 400, 800, and 1200 µmol/l.  
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Fig. 19  Kinetic plot of demethylation of 4-methylaminoantipyrine by recombinant Human CYP1A2 
enzyme. MAA was incubated with human recombinant CYP1A2 enzymes (0.6 pmol/µl) for 20 min and the 
concentrations of 4-methyaminoantipyrine were 25, 50, 100, 400, 800, and 1200 µmol/l.  
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Fig. 20  Intrinsic clearance of 4-methylaminoantipyrine by specific cytochrome P450 enzymes determined 
after incubation of 4-MAA with microsomes expressing human recombinant cytochrome P450 isozymes 
(0.6 pmol/µl) for 20 min. The formation of aminantipyrine (AA) was monitored by HPLC analysis with 
UV detection. Results are given as means of duplicate incubation. 
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Table 15 Enzyme kinetic parameters for metamizole demethylation by cytochrome P450 enzymes. The 
metamizole concentrations was from 25 to 800 µM. The concentration of baculovirus-expressed enzymes 
was 0.6 pmol/µl. All data represent the mean of minimally two experiments. 
 
 
 
 
 
The average immunoquantified levels of the various specific P450s in human liver 
microsomal samples were 25, 42, 1.2, 1.4, 6.7, 16.9, 17.9, 31.3, 2.0, 26.8, 33.6, and 96 
pmol/mg proteins in human liver for the CYP2C19, CYP1A2, CYP1B1, CYP1A1, CYP2D6, 
CYP2C8, CYP2A6, CYP2E1, CYP3A7, CYP2C9, CYP3A5, and CYP3A4 respectively 
(Stormer et al., 2000a). The 4-MAA clearances extrapolated for a typical human liver based 
on the content of specific human CYP enzymes were 4.634, 0.269, 1.199, 0.465, 0.413, 0.588, 
0.510, 1.790, 0.031, 0.614, 0.012 and 0.009 l/min given in the order of cytochrome P450 
enzymes as above. In conclusion of our in vitro investigations, cytochrome P450 2C19 
appeared as the primary enzyme metabolizing metamizole. The data presented here supported 
the results obtained from clinical studies that CYP2C19 is clinically important enzyme 
responsible of the metabolism of a number of therapeutic agents. 
 
Enzyme 
Vmax  
(pmol/pmolCYP/min) 
Km 
 (µmol/l) 
Clint  
(µl/pmol CYP/min) 
Cl extrapolated 
 (l/min) 
CYP2C19 9.5 123 0.077 4.634 
CYP2D6 3.7 138 0.027 0.269 
CYP1A2 8.1 317 0.026 1.199 
CYP1A1 2.6 150 0.017 0.465 
CYP2C8 4 245 0.016 0.413 
CYP2A6 3.8 260 0.015 0.588 
CYP2E1 2.3 169 0.014 0.510 
CYP3A7 2.2 177 0.012 1.790 
CYP2C9 2.2 216 0.010 0.031 
CYP1B1 1.4 193 0.007 0.614 
CYP3A5 1.5 263 0.006 0.012 
CYP3A4 1.6 315 0.005 0.009 
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4.4 Investigations of the metabolism of Aminopyrine by HLM 
 
Aminopyrine  
 
HPLC Analysis. A typical chromatogram of the tested reference substances of 4-
methylaminoantipyrine (4-MAA, peak 1) and 4-dimethylaminoantipyrine (4-DMAA, peak 2) 
measured with HPLC after injection of 20 µl from the standard solution is illustrated in Fig. 
20. As illustrated, the separation was completed within 11 min. The relative order of peak 
retention and retention times were 5.51 min for 4-MAA, 7.07 min for 4- DMAA, and 10.38 
min for the internal standard (sulfaphenazole) as given in Fig. 21. 
 
 
 
 
Fig. 21.   Typical chromatograms of the main metabolite of aminopyrine obtained from standard samples. 
Peak 1: MAA (at 5.51 min) , peak 2: DMAA (at 7.07 min),  peak 3: Internal standard (sulphaphenazole) at 
10.38 min. The mobile phase consisted of 80 % ( v/v) of 25 mM sodium phosphate buffer (pH 6.0), 19 % 
acetonitrile and 1 % (v/v) methanol. The flow rate was 1.0 ml/min. The absorbance was measured at 254 
nm UV detector linked to computer data system. 
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N-demethylation of 4-dimethylaminoantipyrine was firstly studied in human liver microsomes. 
The formation of 4-methylaminoantipyrine from 4-dimethylaminoantipyrine in the human 
liver microsomes increased in protein concentration and time dependent manners. The 
metabolism of 4-dimethylaminoantipyrine was analyzed in difference preparations of human 
liver microsomes (HLM) with many incubations with an incubation time of 20 min, and two 
control incubation samples, firstly without NADPH and secondly with a zero incubation time. 
4-dimethylaminopyrine (200 µmol/l) was incubated with human liver microsomes 10 mg/ml 
of microsomal protein at 37 °C for 20 min and the metabolites were analyzed by HPLC after 
extraction. The metabolites were not seen when 4-dimethylaminoantipyrine and microsomes 
were incubated without NADPH and with NADPH but incubation time (0). Unless specified, 
the standard incubation mixture contained 2.5 mg/ml microsomal protein (the microsomal 
protein stock solution hat 10 mg/ml which was diluted 1 + 3 with the other assay components). 
Incubation was at 37°C for 20 min. A chromatogram showing the formation of 4-
methylaminoantipyrine from 4-dimethylaminoantipyrine by human liver microsomes is 
shown in Fig. 22 and in dependence from substrate concentration in Fig. 23. 
 
 
 
Fig. 22  Extract of aminopyrine and its metabolite analyzed by HPLC with a RP-8 endcapped (5 µm 
particle size) (125 ҳ 4 mm internal dimensions) silica gel column equipped with a pre-column (100 Diol, 5 
µM). The mobile phase consisted of 80 % (v/v) of 25 mM sodium phosphate buffer (pH 6.0), 19% 
acetonitrile and 1% (v/v) methanol. The flow rate was 1.0 ml/min. The absorbance was measured at 254 
nm with an UV-HPLC-detector linked to computer data system. The chromatogram shows the 4-
aminopyrine metabolite 4-MAA formed by the microsomes. In this example, a reaction mixture (100 µl) 
with 2.5 mg/ml of microsomal protein, 1.0 mg/ml of NADPH, and 1 mM of 4-aminopyrine was incubated 
for 20 min at 37°C in 50 mM potassium phosphate buffer (pH 7.4). 4-aminopyrine metabolites were 
extracted and analyzed by HPLC. Peaks: MAA: 5.62 min, DMAA: 7.10 min, I.S: 8.76 min. 
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A maximum biotransformation rate (Vmax) of 443.75 pmol/min/mg (standard deviation 20) 
was measured are given in Fig. 23. The quantity of microsomal protein in one sample was 2.5 
mg protein. The mean Michaelis-Menten constant was Km 472 µmol/l (standard deviation of 
40) µmol/l and intrinsic clearance was 0.94 µl/min/mg (Table. 16). 
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Fig. 23 Plot of the substrate concentration versus metabolite formation rate for demethylation of 4-
dimethylaminoantipyrine by HLM. The reaction mixture (100 µl) included a final concentration of 2.5 
mg/ml HLM protein and 1.0 mg/ml of NADPH. 4-dimethylaminoantipyrine was incubated for 20 min at 
37 °C in 25 mM potassium phosphate buffer (pH 7.4). The concentrations of 4-dimethylaminoantipyrine 
were 25, 50, 400, 800, 1200 µmol/l 4-dimethylaminoantipyrine. 
 
 
 
Table 16.  Enzyme kinetic parameters for aminopyrine demethylation by human liver microsomes. The 
aminopyrine concentration range was from 25 to 800 µmol/l. The protein concentration of HLM protein 
was 2.5 mg/ml. 
 
Preparation KM Vmax Intrinsic clearance 
HL 016 449 455 1.01 
HL 009 472 443 0.94 
HL014 431 424 0.98 
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The chemical inhibition study with human liver microsomes showed a significant inhibitory 
effect on 4-dimethylaminoantipyrine N-demethylation for quinidine and moclobemide (Table 
17 and  Fig. 24).   
 
Table 17  Inhibitory effects of various CYP-specific inhibitors on 4-methylaminoantipyrine formation 
from 4-dimethylaminoantipyrine. The extract from human liver microsomes obtained 20 min after 
incubation with 4-MAA with a concentration of for instance 50 µmol/l with 50 µM from chemical 
inhibitors was monitored by HPLC analysis. Results are presented as average of duplicate incubations. 
The column with % inhibition refers to a substrate and an inhibitor concentration of 50 µM, each. 
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Fig. 24  Plots showing the inhibition of the metabolism of DMAA by quinidine. The reaction mixtures (100 
µl ) contained 2.5 mg/ml of microsomal protein of HLM and 1.0 mg/ml of NADPH and the various 
concentrations of 4-dimethylamino-antipyrine and were incubated for 20 min at 37°C in 25 mM 
potassium phosphate buffer (pH 7.4). 4-dimethylaminoantipyrine metabolites were extracted and 
analyzed by HPLC. 
HLM 
Inhibitors % Inhibition Ki (mM) IC50 (mM) 
Quinidine 60.01 0.05 0.06 
Moclobemide 55.17 0.11 0.13 
Furafylline 28.25 0.22 0.26 
Alpha-naphthoflavone 13.49 0.46 0.55 
Ketoconazole 8.35 0.55 0.66 
Coumarin 6.19 1.10 1.33 
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No major inhibition was observed in incubations with ketoconazole, furafylline, alpha-
naphthoflavone and coumarin.   
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Fig. 25  Inhibition of demethylation of 4-dimethylaminoantipyrine by selective chemical inhibitors of 
CYP450 isoenzymes. Results are presented as arithmetic means of duplicate incubations. 
 
 
The metabolism of 4-dimethylaminoantipyrine was inhibited by 60% and by 55.17 % by a 
concentration of 100 µmo/l of the known CYP2D6 inhibitors quinidine and moclobemide. 
The corresponding Ki values were 0.050 and 0.11 mM, respectively. The corresponding IC50 
values were 0.06, and 0.13 mM respectively. The IC50 values seen with furafylline, alpha-
naphthoflavone, ketoconazole and coumarin were 0.26, 0.55, 0.66 and 1.33 mM and the Ki 
values were 0.22, 0.46, 0.55 and 1.10 mM, respectively (Table 17). These chemical inhibition 
data suggested that CYP2D6 enzyme was primarily responsible for the N-demethylation in 
the metabolism of 4-dimethylaminoantipyrine. 
 
 
 
 
 
 
 
Results 
 
 
 66
4.5 Investigations of the metabolism of aminopyrine by recombinant Human 
CYP 
 
The metabolism of 4-dimethylaminoantipyrine (4-DMAA) was studied in human liver micro-
somes with and without enzyme-specific inhibitors. To confirm the data concerning 
metabolism by CYP2D6, microsomes expressing individual recombinant human P450 
isozymes (CYP1A1, CYP1B1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2-D6, CYP2E1, 
CYP3A4, CYP3A5 and CYP3A7) were incubated with different concentrations of 4-DMAA 
from 25 to 800 µmol/l at 37°C for 20 min. Formation of 4-MAA was observed in the 
incubations with CYP2D6, CYP2C19, CYP1A2, CYP1A1 and CYP1B1, whereas the high 
formation of 4-MAA was observed only with CYP2D6 as given in Fig. 26. 
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Fig. 26  Cytochrome P450 isozymes involved in the in-vitro demethylation of 4-dimethylaminoantipyrine. 
4-DMAA was incubated with microsomes expressing human recombinant P450 isozymes (0.6 pmol/µl) for 
20 min. The 4-dimethylaminoantipyrine concentration range varied from 50 to 800 µM.The formation of 
the 4-methylaminoantipyrine (MAA) was monitored by HPLC analysis with UV detection. Results are as 
average of duplicate incubations. 
 
 
The formation rates of 4-methyaminoantipyrine (4-MAA) with rCYP2D6 were faster than 
with the other P450 isozymes. Also, the highest catalytic efficiency (intrinsic clearance, 
Vmax/Km) was observed with rCYP2D6 (0.011 µl/min/pmol) as illustrated in Fig. 27. 
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Human CYP-metabolism of DMAA
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Fig. 27  Calculated intrinsic clearance of 4-dimethylaminoantipyrine by specific human cytochrome P450 
enzymes after incubation of 4-DMAA with microsomes expressing human recombinant P450 isozymes 
(0.6 pmo/µl) for 20 min. The formation of methylaminantipyrine (MAA) was monitored by HPLC analysis 
with UV detection. Results are given as means of duplicate incubations. 
 
 
 
 
The average immunoquantified levels of the various specific P450s in human liver 
microsomal samples were 6.7, 25, 1.4, 1.2, 42, 33.6, 16.9, 31.3, 26.8, 96, and 2.0 pmol/mg 
proteins in human liver for the CYP2D6, CYP2C19, CYP1A1, CYP1B1, CYP1A2, CYP3A5, 
CYP2C8, CYP2E1, CYP2A6, CYP2C9, CYP3A4 and CYP3A7 respectively(Stormer et al., 
2000a). The correspondingly extrapolated clearances of specific human CYP enzymes in a 
typical human liver were 6.67, 0.37, 1.14, 0.60, 0.34, 0.39, 0.19, 0.0, 0.0, 0.0, 0.0 and 0.0 
l/min, respectively, as given in Table 18. 
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Fig. 27  Kinetic plot of demethylation of 4-dimethylaminoantipyrine by recombinant Human CYP2D6 
enzyme. DMAA was incubated with human recombinant CYP2D6 enzyme (0.6 pmol/µl) for 20 min and 
the concentrations of 4-dimethylaminoantipyrine were 25, 50, 100, 400, 800 µmol/l. The formation of 4-
methylaminantipyrine MAA was monitored by HPLC analysis with UV detection.  
 
Table 18  Enzyme kinetic parameters for aminopyrine methylation by cytochrome P450. The aminopyrine 
concentration range was from 50 to 800 µM. The concentrations of baculovirus-expressed enzymes were 
0.6 pmol/µl and the data represent the mean of two experiments.  
 
In conclusion of our in vitro investigations, cytochrome P450 2D6 appeared as the primary 
enzyme metabolizing methylaminoantipyrine, and a similar effect was observed in all 
incubation in the present studies. 
4-Dimethylaminantipyrine incubation by human P450 isoforms. 
 
Enzyme Vmax (pmol/pmolCYP/min) 
Km 
(µmol/l) 
Cl int 
(µl/ pmol CYP/ min) 
Cl extrapolate 
(l/min) 
CYP2D6 11.9 107 0.11 6.67 
CYP2C19 4.2 169 0.02 0.37 
CYP1A1 5.3 219 0.02 1.14 
CYP1B1 2.7 120 0.02 0.60 
CYP1A2 2.1 155 0.01 0.34 
CYP3A5 1.8 188 0.01 0.39 
CYP2C8 6.4 1280 0.01 0.19 
CYP2E1 0 0 0.00 0.00 
CYP2A6 0 0 0.00 0.00 
CYP2C9 0 0 0.00 0.00 
CYP3A4 0 0 0.00 0.00 
CYP3A7 0 0 0.00 0.00 
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5 DISCUSSION 
 
Aminopyrine and metamizole are used for human therapy in several European countries. In 
addition to the use of these drugs for postoperative pain, they are currently used in self 
medication. Aminopyrine played a key role in the in-vivo study of human hepatic drug 
metabolism, because it was widely used as a probe of liver functionality (Rodzynek et al., 
1986; Lane, 1988) and functional hepatocellular mass (Krahenbuhl et al., 1989) in several 
diseases such as liver cirrhosis (Urbain et al., 1990), chronic hepatitis (Lashner et al., 1988), 
and hepatocarcinoma (Feuer, 1988; Agundez et al., 1994). In agreement with our invitro data 
large, interindividual differences in the capacity to detoxify such drugs have been reported 
(Goldberg and Brown, 1987; Lashner et al., 1988; Cotting et al., 1990; Merkel et al., 1992). 
Considering that the main urinary metabolites in man are acetylated and formylated as shown  
by others (Volz and Kellner, 1980; Cotting et al., 1990; Merkel et al., 1992; Zylber-Katz et al., 
1992; Agundez et al., 1994; Agundez et al., 1995; Costa et al., 2006) who studied in-vivo the 
plasma concentrations of pyrazolones such as aminopyrine and metamizole or metabolism in 
liver disease. We have studied in vitro the oxidative biotransformation of the metamizole and 
aminopyrine by genetically polymorphic enzymes. 
 
5.1 Investigations of the metabolism of metamizole by RLM and HLM 
 
Human liver microsomes (HLM) and rat liver microsomes (RLM) are used widely to 
characterize the role of cytochrome P450s (P450) and other enzymes in drug metabolism. The 
differential centrifugation procedure used to prepare HLM is as follows: Typically, liver 
samples are homogenized and centrifuged at a lower force to form a crude pellet of cell 
debris, nuclei, peroxisomes, lysosomes, and mitochondria (premicrosomal pellet). The 
resulting supernatant is then centrifuged at a higher force to precipitate the microsomes. The 
microsomal pellet is resuspended in a final suspension buffer and is then ready for use. The  
complex metabolism of metamizole has been the subject of many in-vivo studies. However, 
the specific cytochrome P450 enzymes involved catalyzing the formation of 4-AA from 4-
MAA is still not unequivocally identified. 
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The aim of the present study, therefore, was to validate a HPLC method suitable to study the 
formation of metamizole metabolites in RLM and HLM and to get insights into the CYP 
enzymes involved. This first study of  aminopyrine using in-vitro rat liver microsomes was by 
(Imaoka et al., 1988) but with metamizole our investigations may be according to our best 
knowledge the in-vitro investigations of the metabolism of metamizole by RLM, HLM and  
heterologonsly expressed CYP enzymes.  
 
The establishment of appropriate HPLC analytical methods started with the quantification of 
the reference substances of 4-aminoantipyrine and 4- methylaminoantipyrine.  The separation 
was completed with in 13 min. The relative order of retention times was AA at 5.08 min and 
MAA at 6.72 min, as shown in Fig. 6 in results. Similar results were observed in the analysis 
of metamizole metabolites to study their formation in human liver microsomes (Geisslinger et 
al., 1996). For the incubations of metamizole with rat liver microsomes we used two different 
preparations of rat liver microsomes. Mean Vmax (arithmetic mean of 5 incubations) was 
201(standard deviation, SD, 42.2 pmol/mg protein/min) and mean KM was 20.9 (SD 3.8) 
µmol/l are shown in Fig. 8. The corresponding intrinsic clearance was 9.61 µl/mg protein/min 
(SD 3.9). The quantity of microsomes protein was 1.25 mg protein. Analysis of metamizole 
metabolism was performed with hepatic microsomes of untreated male Wistar rats weighing 
between 180 to 220 g, aged 3 months, because the female rats had lower N-demethylation 
activity of 4-methylaminoantipyrine than male rats (Imaoka et al., 1988). The two control 
incubation samples without NADPH and zero incubation time are shown in Fig. 9 at the right 
and left part, respectively. 4-methylaminopyrine (50 µmol/l) was incubated with rat liver 
microsomes 5 mg/ml of microsomal protein at 37°C for 20 min and the metabolites were 
analyzed by HPLC after extraction. The metabolite was not seen when 4-
methylaminoantipyrine and microsomes were incubated without NADPH and with NADPH 
but incubation time zero. This metabolite was almost not seen in an assay system with  
NADPH but its formation inhibited by omeprazole as shown in (Fig. 10). Omeprazole is a 
strong inhibitor of CYP2C19 (Imaoka et al., 1988). In rat liver microsomes, the formation of 
4-aminoantipyrine from 4-methylaminoantipyrine was strongly inhibited by a concentration 
of 50 µM omeprazole (65% inhibition) and to a lesser degree by ketoconazole (37% inhibition) 
but no inhibition was detected with alpha-naphthoflavone, coumarin, quinidine and 
sulphaphenazole (Table 12). Therefore, our results indicated that CYP2C19 represents the 
main contributor to the of metabolism of metamizole in rat liver. 
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Human liver microsomes (HLM) are used widely to characterize the role of cytochrome 
P450s (P450) and other enzymes in drug metabolism. The typical differential centrifugation 
procedure to prepare HLM was used. Liver samples were homogenized and centrifuged at a 
lower force to form a crude pellet of cell debris, nuclei, peroxisomes, lysosomes, and 
mitochondria (premicrosomal pellet). The resulting supernatant was then centrifuged at a 
higher force to precipitate the microsomes. The microsomal pellets was resuspended in a final 
suspension buffer and was then ready for use in incubation studies. The CYP2C subfamily 
accounts for about 18 % of the total adults liver cytochrome P450 content (Shimada et al., 
1994) the major from being CYP2C9 followed by CYP2C19 and CYP2C8 (Goldstein and de 
Morais, 1994; Stormer et al., 2000b). The results of the present study demonstrate that 
fluvoxamine, omeprazole and tranylcypromine were a competitively inhibitors of metamizole 
biotransformation, with ki values of 0.06, 0.06, and 0.15 mM respectively. The metabolism of 
metamizole by human liver microsomes was inhibited by fluvoxamine, omeprazole and 
tranylcypromine by 57.12 %, 51.09 %, and 50 % respectively. A clearly less effective 
inhibition was observed with other P450 isoform-selective inhibitors as shown in Fig. 15. 
Moreover the affinity of MAA to human liver microsomes with the CYP2C19-deficient 
genotype *2/*2 was very low as illustrated in Table 19. The resulting formation of 4-AA was 
compared with the  4-AA formation from the other experiments with the CYP2C19 rapid 
metabolizer genotype (*1/*1) as shown in Fig. 16. Microsomes from Humans with the 
CYP2C19 genotype *2/*2 had low activity in other in vitro studies also (Ibeanu et al., 1998). 
Table 19. The formation of 4-aminoantipyrine from 4-methylaminoantipyrine with HLM with the 
CYP2C19 genotype *2/*2 and HLM with the CYP2C19 genotype *1/*1. The 4-methylaminoantipyrine  
concentration varied from 100 to 1200 µmol/l. 2.5 mg/ml of microsomal protein was used with both 
preparations, with the CYP2C19 genotype (*2/*2) and with the (*1/*1) genotype. Reactions were started 
with 1.0 mg/ml of NADPH and were incubated for 20 min at 37°C in 50 mM potassium phosphate buffer, 
pH 7.4. 4-methylaminoantipyrine metabolites were extracted and analyzed by HPLC 
 
 
 
 
 
 
 
 
 
 
 
[S] 
 
Formation of 4-AA  pmol/mg/min 
 
4-MAA µmol/l 
 
 
HLM CYP2C19 
Genotype (*1/*1) 
 
HLM CYP2C19 
Genotype (*2/*2) 
100 67 52 
400 205 124 
800 300 256 
1200 423 290 
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Our results from the inhibition study indicated the fluvoxamine, omeprazole and 
tranylcypromine are inhibitors of metamizole biotransformation. The overall results from 
human liver microsomes and rat liver microsomes incubation experiments with inhibitors and 
without inhibitors indicated that CYP2C19 was responsible primarily for the metabolism of 4-
methylaminantipyrine. The strong inhibition was observed with human liver microsomes 
when fluvoxamine, omeprazole and tranylcypromine were used as inhibitors ( Fig.15). 
 
5.2 Investigations of the metabolism of metamizole by recombinant human 
CYP 
 
To identify the CYP isozymes involved in the biotransformation of xenobiotics, in vitro 
methods are nowadays frequently used (Huskey et al., 1995). One way to identify the relevant 
enzyme in biotransformation of a given drug is to examine the effect of CYP isozyme-
selective inhibitors on metabolite formation in incubations with liver microsomes expressing 
all cytochrome P450 enzymes. Another way is to use isolated heterologously expressed 
enzymes. To determine in our case the specific CYP enzymes involved in biotransformation 
of the metamizole primary metabolite 4-methylaminoantipyrine, microsomes expressing 
individual recombinant human CYP (CYP1A2, CYP1A1, CYP1B1, CYP2C19, CYP2A6, 
CYP2D6, CYP3A4, CYP3A5, CYP3A7, CYP2C8, CYP2C9 and CYP2E1) were incubated 
with six different concentrations from 4-methylaminoantipyrine in the presence of an 
NADPH-regenerating system at 37°C for 20 min. Under these conditions the highest 
formation rate of 4-aminoantipyrine was observed with CYP2C19 (Fig. 17). The formation 
rates of 4-aminoantipyrine with CYP2C19 were faster than with the other P450 isozymes. 
Also, affinity was the highest among all enzymes tested with a Km of 123 µml/l (Table 15).  
And the extrapolated clearances via specific human CYP2C19, CYP1A2, CYP1B1, CYP1A1, 
CYP2D6, CYP2C8, CYP2A6, CYP2E1, CYP3A7, CYP2C9, CYP3A5, and CYP3A4 
enzymes were 4.634, 0.269, 1.199, 0.465, 0.413, 0.588, 0.510, 1.790, 0.031, 0.614, 0.012 and 
0.009 l/min, respectively. Moreover the enzyme CYP2C19 had the highest catalytic efficiency 
(intrinsic clearance, Vmax/ Km) of measurements (Fig. 20). The results from the contribution of 
individual P 450 isozymes were compared with the inhibition study of metamizole with 
human liver microsomes and rat liver microsomes.  
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The data presented here supported the results obtained from clinical studies that CYP2C19 is 
clinically important enzyme responsible of the metabolism of a number of therapeutic agents 
(Blaisdell et al., 2002) but the effect of CYP2C19 in metabolism of 4-methylaminoantipyrine 
was not known before. Historically, the prototypic probe drug to test for CYP2C19 activity 
was S-mephenytoin, with the S-mephenytoin to R-mephenytoin ratio being an important in 
vivo indicator for that activity (Blaisdell et al., 2002) and it might be a good idea in the future 
to compare that ratio with the metamizole pharmacokinetics in humans. More recently, the 
cytochrome P450 enzyme 2C19 was identified as an important enzyme of the cytochrome 
P450 superfamily being responsible for the biotransformation and elimination of many 
commonly prescribed drugs including anticonvulsants, antidepressants, the antimalaria-drug 
proguanil, and all currently medically used proton pump inhibitors (Goldstein and de Morais, 
1994; Streetman et al., 2000). It is interesting that our study adds the analgesic and antipyretic 
drug metamizole to that list of CYP2C19 substrates. 
 
5.3 Investigations of the metabolism of aminopyrine by HLM 
This study started with establishment of HPLC analysis based on the reference substances 4- 
methylaminoantipyrine and 4-dimethylaminoantipyrine (aminopyrine). The separation is 
illustrated in Fig. 21 in results. The metabolism of 4-dimethylaminoantipyrine was analyzed 
in different preparations of human liver microsomes (HLM) with many incubations with an 
incubation time of 20 min and two control incubation samples without NADPH and zero time 
of incubation. 4-dimethylaminopyrine (200 µmol/l) was incubated with human liver 
microsomes with a microsomal protein concentration of 2.5 mg/ml at 37 °C for 20 min and 
the metabolite 4-methylaminoantipyrine was analyzed by HPLC after extraction. The 
metabolites were not seen when 4-dimethylaminoantipyrine and microsomes were incubated 
without NADPH and also not in incubations with NADPH but with and incubation time of 
zero. The kinetics of 4-dimethylaminoantipyrine N-demethylation in the human liver 
microsomes is illustrated in Fig. 23 in the results. A maximum biotransformation rate (Vmax) 
of 443.75 pmol/min/mg (standard deviation 20) was measured. The mean Michaelis-Menten 
constant  was 472.25 µmol/l (40 µmol/l standard deviation) and intrinsic clearance was 0.94 
µl/min/mg. Km In the chemical inhibition study with human liver microsomes, the drugs 
quinidine and moclobemide exhibited an inhibitory effect on 4-dimethylaminoantipyrine 
demethylation.  
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Quinidine is known to be a specific inhibitor of the enzyme CYP2D6 at low concentrations 
whereas moclobemide is an inhibitor of CYP2C19 and CYP2D6 and slightly also CYP1A2 
(Baker et al., 1999). The metabolism of 4-dimethyl-aminoantipyrine was inhibited by 60% 
and 55% by a concentration of 100 µmo/l of the known CYP2D6 inhibitors quinidine (Fig. 24) 
and moclobemide and with Ki values of 0.050 and 0.11 mM respectively. A similar value of 
Ki of quinidine was observed (0.03) in the similar study (Smith and Jones, 1992) with the test 
substrate alprenolol. The corresponding IC 50 values were 0.06, and 0.13 respectively. The 
IC50 value seen with furafylline, alpha-naphthoflavone, ketoconazole and coumarin were 0.26, 
0.55, 0.66 and 1.33 and the ki values were 0.22, 0.46, 0.55 and 1.10 mM respectively (Table 
17). These chemical inhibition data suggested that CYP2D6 was primarily responsible for the 
metabolism of 4-dimethylaminoantipyrine since quinidine is a highly potent selective 
inhibitor of CYP2D6 (Abraham et al., 2001). Also in other studies for instance (Brachtendorf 
et al., 2002), the inhibition data set suggests that CYP2D6 is the high affinity and CYP2 C19 
is the low affinity binding site, respectively, for another drug, namely maprotiline. The data 
presented are inter preted based on the results obtained from clinical studies, which showed 
the quinidine is the most potent inhibitor of enzyme CYP2D6 (Lennard, 1990; Smith and 
Jones, 1992) (Abraham et al., 2001). 
 
5.4 Investigations of the metabolism of aminopyrine by recombinant Human 
CYP 
Aminopyrine N-demethylation activity has been studied in humans mainly by use of the 
aminopyrine breath test, although in vitro studies remain to be done (Chengelis, 1988). 
Therefore we performed our complete in-vitro study on the metabolism of aminopyrine by 
human liver microsomes and specific human cytochrome P450 enzymes. Some formation of 
the 4-DMAA metabolite 4-MAA was observed in the incubations with CYP2D6, CYP2C19, 
CYP1A2, CYP1A1 and CYP1B1, and the highest formation of 4-MAA was observed with 
CYP2D6 as shown in Fig. 26 in the results. The average of immuno-quantified levels of the 
various specific P-450s in human liver microsomal samples were 6.7, 25, 1.4, 1.2, 42, 33.63, 
16.85, 31.29, 26.82, 96, and 2.0 pmol/mg proteins in human liver for the CYP2D6, CYP2C19, 
CYP1A1, CYP1B1, CYP1A2, CYP3A5, CYP2C8, CYP2E1, CYP2A6, CYP2C9, CYP3A4 
and CYP3A7 respectively (Shimada et al., 1994; Mizutani, 2003), and the extrapolated 
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clearances via the specific human CYP enzymes were 6.67, 0.37, 1.14, 0.60, 0.34, 0.39, 0.19, 
0.0, 0.0, 0.0, 0.0 and 0.0 l/min, respectively, as shown in Fig. 27. 
In conclusion of our in-vitro investigations, cytochrome P450 2D6 appeared to be the primary 
enzyme metabolizing 4-dimethylaminoantipyrine. And concerning CYP2D6 a similar and 
consistent effect was observed in all incubations in the present studies, namely with chemical 
inhibitors and with the isolated enzymes as well. Since CYP2D6 is responsible for the 
metabolism of many commonly used drugs, this may result may mean that the so-called poor 
metabolisers of substrates of CYP2D6, which are about 7% in Caucasian populations (see 
introduction) are at high risk for side effects of antipyrine (aminopyrine). The results obtained 
here on the impact of CYP2D6 for the biotransformation  and elimination of analgesic- 
antipyretic drugs complements the results of many other studies showing that many 
antiarrhythmics, ß- receptor blockers, neuroleptics, anti-depressants, tamoxifen, and codeine 
are metabolized by CYP2D6 (Allegaert et al., 2005; Komura and Iwaki, 2005). Our results are 
in slight contrast with the data of (Niwa et al., 1999) who concluded that CYP2C19 is the 
most efficient enzyme in demethylation of aminopyrine and that CYP2C8 and CYP2D6 may 
also be involved.  
 
However, Niwa et al. did not specifically measure the metabolite formed but they only 
quantified the reaction by the formaldehyde production and thus, it is not clear which of the 
two aminopyrine demethylations they really measured. Altogether, these findings suggest that 
CYP2C19 and CYP2D6 are clinically important enzymes responsible for the biotrans-
formation (metabolism) of a number of therapeutic agents belonging to the class of analgesic-
antipyretic drugs.  
 
5.5 Clinical Implications and Conclusion 
 
Metamizole and aminopyrine are usually used episodically for treatment of acute pain and 
fever, although prolonged use for musculokeletal pain or the control of pain in patients with 
cancer is also practised (Rodriguez et al., 1994) and (Planas et al., 1998). The drugs are 
widely used in some countries, while in others (for instance in Sweden) they have been 
banned or restricted because of the risk of adverse effects, notably agranulocytosis (Zylber-
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Katz et al., 1995). However, it have been estimated by the an international study of 
agranulocytosis and aplastic anemia that the excess risk of agranulocytosis associated with 
eny metamizole and aminopyrine exposure in one treatment week is 1.1 cases per million user 
(Levy et al., 1995).  
The same studies did not find an association between aplastic anaemia and metamizole and 
aminopyrine use, but only for agranulocytosis. The data of this study indicates that highly 
polymorphic enzymes are involved in biotransformation of these antipyretic drugs. As 
mentioned earlier, about 3% of most population do not have CYP2C19 activity and about 7% 
of many population do not have CYP2D6 activity. It is an interesting hypothesis that these 
slow metabolizers have a high risk for the adverse effect but this was never tested in clinical 
studies. 
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6 SUMMARY 
Two formerly very frequently used analgesic drugs or active metabolites of analgesic drugs, 
namely 4-methylaminoantipyrine (derived from metamizole) and 4-dimethylaminoantipyrine 
(also termed antipyrine) were studied here concerning the specific enzymes involved in their 
oxidative biotransformation by genetically polymorphic and non-polymorphic enzymes. The 
main conclusions from this investigation are: 
• In vitro metabolism of methylaminoantipyrine to 4-aminoantipyrine was characterized 
by a Km of 20.9 µmol/l and a Vmax of 201 pmol/mg/min in rat liver microsomes (1.25 
mg/ml protein). Strongest inhibition of methylaminoantipyrine demethylation in rat 
liver microsomes was achieved with omeprazole with an IC50 of 0.05 mM 
• In human liver microsomes, mean Km and Vmax were 154 µmol/l and 143 
pmol/mg/min, respectively (2.5 mg/ml protein). Strong inhibition of these reactions 
was observed after co-incubation with omeprazole (CYP2C19), fluvoxamine 
(CYP2C19 and CYP1A2), and tranylcypromine (CYP2C19) with IC50 values of 0.07, 
0.07 and 0.18 mmol/l, respectively. 
• Some formation of 4-aminoantipyrine from methylaminoantipyrine was observed in 
the incubations with recombinant CYP2C19, CYP2D6, CYP1A2, CYP2C8, CYP2A6, 
CYP1A1, CYP1B1, CYP3A4, CYP3A5, CYP3A7, CYP2C9 and CYP2E1 but the 
highest formation was observed with CYP2C19. Intrinsic clearances were 0.077 
(CYP2C19), 0.027 (CYP2D6), 0.026 (CYP1A2), 0.017 (CYP1A1) and 0.016 
(CYP2C8) µl/min/pmol CYP, respectively. 
• It is concluded that CYP2C19 is the most important cytochrome P450 enzyme 
involved in metamizole metabolism but the enzymes CYP2D6  and CYP1A2 may also 
be involved. 
• In human liver microsomes, mean Km and Vmax for the demethylation of 
dimethylaminoantipyrine (Aminopyrine) to methylaminoantipyrine were 472 µmol/l 
and 443 pmol/mg/min, respectively (2.5 mg/ml protein). S inhibition of these reactions 
was observed after co-incubation with quinidine (a prototypic CYP2D6 inhibitor), and 
moclobemide.  
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• The formation of 4-methylaminoantipyrine from dimethylaminoantipyrine was 
observed in the incubations with recombinant CYP2D6, CYP2C19, CYP1A1, 
CYP1B1, CYP1A2, CYP3A5 and CYP2C8, but the highest formation was observed 
with CYP2D6 with an intrinsic clearance of 0.11 µl/pmol CYP/min. Intrinsic 
clearances via CYP2C19, CYP1A1 and CYP1B1 were significantly lower with values 
of 0.02 µl/pmol CYP/min for all these three enzymes. 
• In slight contrast to earlier data of Niwa et al, we concluded that CYP2D6 may be the 
most important enzyme responsible for the N-demethylation of 4-dimethyl-
aminoantipyrine (aminopyrine) to 4-methylaminoantipyrine in human hepatic 
biotransformation. 
Altogether, these findings suggest that CYP2C19 and CYP2D6 are medically important 
enzymes responsible for the metabolism of therapeutic agents on the analgesic-antipyretic 
drugs, metamizole and aminopyrine and the role of the genetic polymorphisms in the genes 
coding for these enzymes for adverse effects should be further studied. 
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7 FUTURE PERSPECTIVES 
 
The work presented in this thesis is part of clinical pharmacology studies and the clinical of 
pharmacology is the application of pharmacodynamics and pharmacokinetics to patients with 
diseases and nowadays pharmacogenetics plays an important role in this therapeutic research. 
The clinical pharmacologists are using data from the human genome project to determine how 
and why individuals respond differently to drugs and pharmacogenetics is one of the fields of 
clinical pharmacology, which studies how genetic factors influence drug response. Today, the 
relationship between dosage requirements and pharmacogenetic polymorphisms in drug 
metabolizing enzymes are best substantiated for cytochromes such as CYP2D6 (anti-
depressants, antipsychotics, analgesics) (Kirchheiner et al., 2004; Lotsch et al., 2004; 
Ingelman-Sundberg, 2005) , CYP2C9 (warfarine, antidiabetics) (Kirchheiner et al., 2004) 
CYP2C19 (diazepam, proton pump inhibitors) (Goldstein, 2001; Desta et al., 2002). 
CYP2C19 is clinically important enzyme responsible of the metabolism of a number of 
therapeutic agents (Blaisdell et al., 2002). CYP2 family plays a dominant role in the 
metabolic elimination of more xeno and endobiotics than anyother biotransformation. The 
CYP2C subfamily in human consists of four highly homologous genes: CYP2C8, CYP2C9, 
CYP2C18 and CYP2C19. CYP2C accounts for about 17-20 % of the human total liver CYP 
content. CYP2C9 is the main CYP2C in human liver, followed by CYP2C8 and CYP2C19 
(Edwards, 1998). I was interested to investigate the impact of CYP2 genetic polymorphisms 
for human on other drugs of analgesic-antipyretic drugs, and the contribution of CYP2C19, 
CYP2D6 and CYP1A2 on the in-vivo hepatic metabolism of metamizole and aminopyrine 
with different sources of cytochrome P450 should be compared between in-vitro and in-vivo 
methods in hepatic metabolism. This is also quite interesting because aminopyrine and 
metamizole have been widely used as a probe of liver functionality (Feuer, 1988). In addition, 
recently there is growing interest in the use of metamizole and aminopyrine metabolism as 
indicator of the outcome of hepatic transplantation.  
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